aripiprazole has been researched along with olanzapine in 389 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 111 (28.53) | 29.6817 |
| 2010's | 202 (51.93) | 24.3611 |
| 2020's | 76 (19.54) | 2.80 |
| Authors | Studies |
|---|---|
| Ernsberger, P; Hufeisen, SJ; Jayathilake, K; Kroeze, WK; Meltzer, HY; Popadak, BA; Renock, SM; Roth, BL; Steinberg, S | 1 |
| Huang, AS; Kim, SF; Snowman, AM; Snyder, SH; Teuscher, C | 1 |
| Agai-Csongor, E; Bielik, A; Domány, G; Galambos, J; Gémesi, L; Greiner, I; Gyertyán, I; Ignácz-Szendrei, G; Keseru, GM; Kiss, B; Laszlovszky, I; Laszy, J; Magdó, I; Nógrádi, K; Sághy, K; Schmidt, E; Vágó, I; Zájer-Balázs, M | 1 |
| Coolen, HK; Glennon, JC; Kruse, CG; Lange, JH; Reinders, JH; Tolboom, JT | 1 |
| Andreasen, JT; Bernetti, M; Borriello, M; Brindisi, M; Butini, S; Cagnotto, A; Campiani, G; Ceres, N; Coccone, SS; De Angelis, M; Fattorusso, C; Fiorini, I; Franceschini, S; Gemma, S; Mennini, T; Mikkelsen, JD; Nacci, V; Novellino, E; Ros, S; Sandager-Nielsen, K; Scheel-Kruger, J; Trotta, F | 1 |
| Pettersson, F; Pontén, H; Sonesson, C; Waters, N; Waters, S | 1 |
| Borrelli, G; Butini, S; Campiani, G; Fattorusso, C; Fiorini, I; Franceschini, S; Gemma, S; Guarino, E; Jacobsen, TA; Kumar, V; Madsen, K; Novellino, E; Orteca, N; Persico, M; Sandager-Nielsen, K; Scheel-Kruger, J; Trotta, F | 1 |
| Jensen, AA; Kehler, J; Krogsgaard-Larsen, N | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Sen, S; Sinha, N | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bienkowski, P; Bucki, A; Jaśkowska, J; Kazek, G; Kowalski, P; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Mitka, K; Pawłowski, M; Siwek, A; Wasik, A; Wesołowska, A | 1 |
| Andreassi, M; Brindisi, M; Brogi, S; Butini, S; Cagnotto, A; Campiani, G; Casagni, A; Franceschini, S; Gemma, S; Gorelli, B; Mikkelsen, JD; Novellino, E; Ros, S; Salmona, M; Sandager-Nielsen, K; Saponara, S; Scheel-Kruger, J; Trotta, F; Weikop, P | 1 |
| Deng, X; Fu, W; Guo, L; Xu, L; Yu, K; Zhao, W; Zhen, X | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Albert, MJ; Baldessarini, RJ; Centorrino, F; Kelleher, JP | 1 |
| Kalkman, HO; Loetscher, E | 1 |
| Woods, SW | 1 |
| Hedges, D; Jeppson, K; Whitehead, P | 1 |
| Tamminga, CA | 1 |
| Altar, CA; Dunn, R; Jordan, S; Kikuchi, T; Koprivica, V; Tottori, K | 1 |
| Buckley, PF; Glazer, W; Sebastian, CS | 1 |
| Duggal, HS | 1 |
| Ismail, MS; Profenno, LA; Tariot, PN | 1 |
| Altar, CA; Burris, KD; Hirose, T; Kikuchi, T; Kitagawa, H; Miwa, T; Nabeshima, T; Uwahodo, Y; Yamada, S | 1 |
| Andrade, C | 1 |
| Bryois, Ch; Sahli, Ch | 1 |
| Shayegan, DK; Stahl, SM | 1 |
| Citrome, L; Volavka, J | 1 |
| Finkel, S | 1 |
| Katz, IR | 1 |
| Archibald, D; Carson, WH; Gharbia, NA; Jody, D; Marcus, R; McQuade, RD; Stock, E; Vanveggel, S | 1 |
| Keck, PE | 1 |
| Vieta, E | 1 |
| Dubois, D | 1 |
| Kuehn, BM | 1 |
| Britt, CS; Daniels, AJ; Grizzle, MK; Ignar, DM; Jones, DN; Kalinichev, M; Rourke, C | 1 |
| Berk, M; Bourin, M; Dodd, S; Ivanovski, B; Lagopoulos, J; Malhi, GS; Mitchell, PB | 1 |
| Balit, CR; Isbister, GK; Kilham, HA | 1 |
| Howland, RH | 1 |
| Dunlop, J; Kowal, DM; Lou, Z; Nawoschik, SP; Zhang, JY | 1 |
| Annable, L; Beauclair, L; Chouinard, G; Kolivakis, TT; Margolese, HC; Miller, R | 1 |
| Ballard, C; Waite, J | 1 |
| Dagerman, K; Insel, PS; Schneider, LS | 1 |
| Harms, E; Kropp, S; Luebbe, G; Ziegenbein, M | 1 |
| Doraiswamy, PM; Levine, JG; Szarfman, A; Tonning, JM | 1 |
| Ali, M; Carson, WH; Cornblatt, BA; Green, MF; Kern, RS; Marcus, R; McQuade, RD; Owen, JR | 1 |
| Cipriani, A; Geddes, JR; Rendell, JM | 1 |
| Ehret, MJ; Levin, GM | 1 |
| Bies, RR; Chew, ML; Gharabawi, G; Greenspan, A; Kapur, S; Kirshner, MA; Lehman, ME; Mulsant, BH; Pollock, BG | 1 |
| Chou, JC; Fazzio, L | 1 |
| Chrzanowski, WK; Marcus, RN; McQuade, RD; Nyilas, M; Torbeyns, A | 1 |
| Kovács, G; Kovács, L | 1 |
| Chavez, B; Poveda, RA | 1 |
| De Oliveira, IR; Juruena, MF | 1 |
| Citrome, L; Jaffe, A; Levine, J | 1 |
| Engel, JA; Fejgin, K; Klamer, D; Pålsson, E; Safonov, S; Svensson, L; Wass, C | 1 |
| Limosin, F | 1 |
| Fiedler, U; Wolf, J | 1 |
| Bourgeois, JA; Kahn, D | 1 |
| Flood, DG; Gasior, M; Marino, MJ | 1 |
| Assis, LC; Barbosa, LM; Grandi, E; Quevedo, J; Rezin, GT; Streck, EL | 1 |
| Wooten, J | 1 |
| Deng, C; Han, M; Huang, XF; Newell, K; Zavitsanou, K | 1 |
| Chen, CH; Huang, MC; Lu, ML | 1 |
| Allen, MH; Nordstrom, K | 1 |
| Jain, R; Skale, TG | 1 |
| Carson, WH; Casey, DE; Kan, HJ; L'Italien, GJ; Marcus, RN | 1 |
| Avorn, J; Brookhart, MA; Choudhry, NK; Mogun, H; Patrick, A; Schneeweiss, S; Setoguchi, S; Wang, PS | 1 |
| Perlis, RH | 1 |
| Bushe, CJ; Leonard, BE | 1 |
| Thone, J | 1 |
| Citrome, L | 2 |
| Papakostas, GI; Shelton, RC | 1 |
| Neill, JC; Reynolds, GP; Snigdha, S; Thumbi, C | 1 |
| Calabrese, JR; Gajwani, P; Ganocy, SJ; Gao, K; Kemp, DE; Muzina, DJ | 1 |
| Gregoriou, S; Karagiorga, T; Kontochristopoulos, G; Rigopoulos, D; Stratigos, A; Volonakis, K | 1 |
| De Hert, M; Hanssens, L; Peuskens, J; Scheen, A; Van Eyck, D; van Winkel, R; Wampers, M | 1 |
| Burne, TH; Deng, C; Han, M; Huang, XF; Newell, KA | 1 |
| Dal-Pizzol, F; Gomes, KM; Martins, MR; Petronilho, FC; Quevedo, J; Streck, EL | 1 |
| Corey-Lisle, PK; Crosby, RD; Kan, HJ; Kolotkin, RL; McQuade, RD | 1 |
| Andreazza, AC; Kapczinski, F; Quevedo, J; Rosa, MI; Stertz, L; Streck, EL; Valvassori, SS | 1 |
| Findling, RL | 1 |
| Erickson, CA; McDougle, CJ; Posey, DJ; Stigler, KA | 1 |
| Sikich, L | 1 |
| Croarkin, PE; Emslie, GJ; Mayes, TL | 1 |
| Berman, RM; Breder, C; Campos, JA; Carson, WH; Kerselaers, W; L'italien, GJ; Marcus, RN; McQuade, RD; Newcomer, JW; Nys, M | 1 |
| Aliaga, M; Assié, MB; Barbara, M; Bardin, L; Carilla-Durand, E; Malfètes, N; Maraval, M; Newman-Tancredi, A | 1 |
| Abe, M; Egashira, N; Fujiwara, M; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Oishi, R; Okuno, R | 1 |
| Bogeski, M; Gogos, A; van den Buuse, M | 1 |
| Ayache, L; Buysschaert, M; Fagnart, O; Feys, JL; Gruson, D; Hermans, MP; Jamart, J; Luts, A; Mertens de Wilmars, S; Misson, A; Oriot, P | 1 |
| Bruggeman, R; Postema, R; Schilthuis, M; Schorr, SG; Slooff, CJ; Taxis, K; Van Oven, W | 1 |
| Kusnir, D; LoPiccolo, M; Sandoz, A; Tausk, FA | 1 |
| Cretaz, E; Diniz, BS; Forlenza, OV | 1 |
| Baardewijk, Mv; Davies, A; L'italien, GJ; Loze, JY; Sennfalt, K; Vardeva, K | 1 |
| Baker, RA; Carson, WH; Crandall, DT; Eudicone, JM; L'italien, G; Marcus, RN; McQuade, RD; Meyer, JM; Newcomer, JW; Pikalov, A; Vester-Blokland, E | 1 |
| Marshall, PB; Mellman, TA; Nguyen, SX | 1 |
| Archibald, D; Carson, WH; Fleischhacker, WW; Marcus, RN; McQuade, RD; Swanink, R | 1 |
| Chen, L; Kinon, BJ; Kollack-Walker, S; Sniadecki, J; Stauffer, VL | 1 |
| Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, AL; Rosenheck, RA; Stroup, TS; Swartz, MS | 1 |
| Baker, RA; Byerly, MJ; Eudicone, JM; Marcus, RN; Tran, QV; Whitehead, R | 1 |
| Hanssens, L; Kerselaers, W; L'Italien, G; Loze, JY; Marcus, RN; Pans, M | 1 |
| Baker, RA; Kim, E; Meyer, JM; Rosenblatt, LC; Whitehead, R | 1 |
| Deng, C; Han, M; Huang, XF | 1 |
| Bogers, JP; Starrenburg, FC | 1 |
| Khalid, I; Khalid, TJ; Rana, L; Roehrs, T | 1 |
| Breier, A; Kane, JM; Kryzhanovskaya, LA; Osuntokun, O; Stauffer, VL; Watson, SB; Xu, W | 1 |
| Carlström, EL; Jazin, E; Jiang, L; Saetre, P | 1 |
| Ascher-Svanum, H; Ball, T; Conley, R; Liu, L; Stauffer, V | 1 |
| Kumar, R; Sachdev, PS | 1 |
| Auclair, AL; Barret-Grévoz, C; Barreto, M; Depoortère, R; Kleven, MS; Newman-Tancredi, A | 1 |
| Heard, K; Hoppe, J; Tan, HH | 1 |
| Arvilommi, P; Isometsä, E; Leppämäki, S; Mantere, O; Suominen, K; Valtonen, HM | 1 |
| Borba, CP; Boxill, R; Cather, C; Copeland, PM; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Henderson, DC; Sharma, B | 1 |
| DeLorenze, G; L'Italien, G; McQuade, R; Newcomer, J; Oliveria, SA; Quesenberry, CP; Tsai, AL; Willey, VJ; Yood, MU | 1 |
| Jing, Y; Kim, E; Pikalov, A; Tran, QV; You, M | 1 |
| Cohen, D; Correll, CU | 1 |
| Englisch, S; Inta, D; Weinbrenner, A; Zink, M | 1 |
| Cruz, N; Goikolea, JM; Sanchez-Moreno, J; Torres, F; Valentí, M; Vieta, E | 1 |
| Deng, C; du Bois, TM; Han, M; Huang, XF | 1 |
| El-Sayeh, HG; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Correll, CU; Kane, JM; Malhotra, AK; Manu, P; Napolitano, B; Olshanskiy, V | 1 |
| Assunção-Talbott, S; Barnes, TR; Buckley, P; Correll, CU; Eudicone, J; Kane, JM; McQuade, R; Pikalov, A; Sachs, G; Tran, QV | 1 |
| Conley, Y; Davies, MA; Roth, BL | 1 |
| Helm, ME; Henderson, C; Martin, BC; Pathak, P; West, D | 1 |
| Fujita, K; Fukuo, Y; Furukawa, O; Iwata, N; Kawashima, K; Kishi, T; Kitajima, T; Moriwaki, M; Naitoh, H; Okochi, T | 1 |
| Hori, H; Ikenouchi-Sugita, A; Nakamura, J; Ueda, N; Umene-Nakano, W; Yoshimura, R | 1 |
| Duggan, L; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Benedetti, AM; Frazee, LA; Leung, JG; Myers, N | 1 |
| Elsom, SJ; Gurvich, C; Kulkarni, J; McCauley-Elsom, K | 1 |
| Fleischhacker, WW; Hoertnagl, C; Hofer, A; Pfaffenberger, N | 1 |
| Remington, G | 1 |
| Guirguis-Blake, J | 1 |
| Lazarus, A; Quon, P; Tafesse, E; Woodward, TC | 1 |
| Chen, J; Deng, C; Hu, C; Huang, XF | 1 |
| Konstantakopoulos, G; Kouzoupis, AV; Mourikis, I; Oulis, P; Papageorgiou, SG | 1 |
| Lai, CH | 1 |
| Davis, JM; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Lobos, CA; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Jackson, CW; Lorenz, RA; Saitz, M | 1 |
| Gen, K; Inoue, Y; Suzuki, H | 1 |
| Claes, S; De Hert, M; Martens, GJ; Moons, T; Peuskens, J; Van Loo, KM; Van Schijndel, JE; van Winkel, R | 1 |
| Ardizzone, I; Carratelli, TI; Ferrara, M; Marconi, A; Nardecchia, F | 1 |
| Calcagno, E; Carli, M; Invernizzi, RW; Mainini, E; Mainolfi, P | 1 |
| Bastiampillai, T; Lander, M | 1 |
| Brecher, M; Calabrese, JR; Carlson, BX; Edwards, S; Eudicone, JM; Evoniuk, G; Ganocy, SJ; Jansen, W; Kemp, DE; Leon, AC; Minkwitz, M; Pikalov, A; Stassen, HH; Szegedi, A; Tohen, M; Van Willigenburg, AP | 1 |
| Chen, J; Gao, K; Kemp, DE | 1 |
| Fernalld, R; Jordan, S; Kambayashi, J; Kikuchi, T; Koprivica, V; Murphy, JJ; Regardie, K; Wolff, C | 1 |
| Case, M; Conley, RR; Hoffmann, VP; Jacobson, JG; Stauffer, VL | 1 |
| Ascher-Svanum, H; Faries, DE; Kane, JM; Osuntokun, OO; Peng, X; Stauffer, VL; Stensland, MD | 1 |
| McKinney, C; Renk, K | 1 |
| Correll, CU | 1 |
| Lee, SY; Pae, CU; Park, MH; Patkar, AA | 1 |
| Cohn, T; Faulkner, G; Mukundan, A; Remington, G | 1 |
| Depping, AM; Gaudchau, A; Kissling, W; Komossa, K; Leucht, S | 1 |
| Lee, J; Ng, KW; Swapna, V | 1 |
| Kim, LW; Kim, YH; Lee, BJ; Lee, CH; Lee, JG; Park, SW; Shin, BS | 1 |
| Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Bobo, WV; Crystal, S; Gerhard, T; Huang, C; Lieberman, JA; Olfson, M | 1 |
| Englisch, S; Esslinger, C; Meyer-Lindenberg, A; Rausch, F; Schirmbeck, F; Zink, M | 1 |
| Ahn, YM; Jung, DC; Kang, UG; Kim, EY; Kim, SH; Kim, YS; Lee, NY; Sung, KH; Yu, HY | 1 |
| Andel, R; Becker, MA; Boaz, TL; Chandler, K; Desmarais, SL; Howe, A; Van Dorn, RA | 1 |
| Barbato, A; D'Avanzo, B; Parabiaghi, A; Tettamanti, M | 2 |
| Eriksson, J; Kasteng, F; Lindgren, P; Sennfält, K | 1 |
| Kaneda, A; Kaneko, S; Sugawara, N; Tomita, T; Yasui-Furukori, N | 1 |
| Fukui, N; Ono, S; Sawamura, K; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J | 1 |
| Hamer, RH; LaVange, LM; Lieberman, JA; McEvoy, JP; Nussbaum, AM; Perkins, DO; Ring, KD; Rosenheck, RA; Stroup, TS; Swartz, MS | 1 |
| Eberhard, J; Fors, BM; Hansen, K; Lindström, E; Sapin, C | 1 |
| Bagalman, E; Carls, GS; Curkendall, SM; Forbes, RA; Hebden, T; Jing, Y; Kalsekar, I; Thase, ME | 1 |
| Berge, RK; Diéguez, C; Fernø, J; Fjær, S; López, M; Lunder, N; Pavlin, T; Skrede, S; Steen, VM; Vázquez, MJ; Vidal-Puig, A | 1 |
| Faludi, G; Fejes, L; Inczédy-Farkas, G; Kassai-Farkas, A; Lazáry, J; Makkos, Z | 1 |
| Weiden, PJ | 1 |
| Cho, HY; Fang, ZH; Kim, YH; Lee, BJ; Lee, CH; Lee, JG; Park, SW; Phuong, VT; Seo, MK | 1 |
| Diaz-Atienza, F; Gurpegui, M; Gutiérrez-Rojas, L; Jurado, D; Martínez-Ortega, JM | 1 |
| Christoffersen, RK; Høimark, L; Vesterby, A; Vestergård, LD | 1 |
| Bschor, T; Erbe, S; Gutwinski, S | 1 |
| Berkowitz, RL; Docherty, JP; Ni, Q; Parks, JJ; Patel, U | 1 |
| Jindal, KC; Munjal, V; Singh, GP | 1 |
| Han, C; Jeong, HG; Joe, SH; Ko, YH; Lee, HY; Lee, MS | 1 |
| Knoepflmacher, D; Shapley, L; Turner, EH | 1 |
| Dunn, G; French, P; Hutton, P; Morrison, AP; Taylor, PJ; Yung, AR | 1 |
| Magno Zito, J; Safer, AM; Safer, DJ | 1 |
| Abdallah, CG; Hong, X; Huang, H; Huang, Q; Jiang, L; Liang, C; Liu, Y; Wan, X; Wang, J; Wu, R; Xu, C; Zhang, J | 1 |
| Azorin, JM; Gasquet, I; Gierski, F; Leguay, D; Lemogne, C; Limosin, F; Raucher-Chéné, D; Rouillon, F; Schuster, JP | 1 |
| Akhtar, U; Ambrosini, PJ; Lobach, L; Oluwabusi, OO; Youngman, B | 1 |
| Chen, CK; Hsiao, CC; Huang, YS; Ree, SC; Wang, LJ | 1 |
| Capapey, J; Colom, F; Goikolea, JM; Grande, I; Sanchez-Moreno, J; Torres, I; Undurraga, J; Valentí, M; Vieta, E | 1 |
| Blagojević, D; Lečić-Toševski, D; Miljević, Č; Niketić, V; Nikolić, M; Nikolić-Kokić, A; Spasić, MB | 1 |
| Arndt, S; Glorioso, DK; Golshan, S; Henry, R; Jeste, DV; Jin, H; Kraemer, HC; Mudaliar, S; Shih, PA | 1 |
| Bouvard, S; Ciumas, C; d'Amato, T; Daléry, J; Lerond, J; Lothe, A; Poulet, E; Ryvlin, P; Saoud, M | 1 |
| Bienroth, M; Curtis, V; Debenham, M; George, M; Gonzalez, D; Jones, S; Pitsi, D | 1 |
| Bader, M; Klingerman, CM; Lynch, CJ; Stipanovic, ME | 1 |
| Honaker, J; Lohr, WD | 1 |
| Byerly, MJ; Glick, ID; Hamer, RM; Khan, AY; Lamberti, JS; McEvoy, JP; Nasrallah, HA; Ray, N; Steinbook, RM; Stroup, TS | 1 |
| Cheung, C; Chua, SE; Collier, DA; Deng, W; Gong, Q; Huang, C; Jiang, L; Li, M; Li, T; Ma, X; McAlonan, GM; Sham, PC; Wang, Q; Wang, Y | 1 |
| El-Sayeh, HG; Hunger, H; Khanna, P; Komossa, K; Leucht, S; Rummel-Kluge, C; Schwarz, S | 1 |
| Couchman, L; Fisher, DS; Flanagan, RJ; Handley, SA; Morgan, PE; Partridge, SJ | 1 |
| Golla, H; Perrar, KM; Voltz, R | 1 |
| Aitchison, KJ; Almandil, NB; Besag, FM; Liu, Y; Murray, ML; Wong, IC | 1 |
| Fukui, N; Ono, S; Saito, M; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J | 1 |
| Cichocki, M; Jarmuszkiewicz, Z; Kus, K; Nowakowska, E; Ratajczak, P; Woźniak, A | 1 |
| Fisher, DS; Flanagan, RJ; Handley, SA; Partridge, SJ | 1 |
| Adams, DH; Baygani, S; Kinon, BJ; Kollack-Walker, S; Millen, BA; Velona, I; Walling, DP | 1 |
| Fuller, C; Grudziak, J; Nguyen, HL; Rickels, K; Rickels, MR; Teff, KL | 1 |
| Hashiguchi, M; Kunitomi, T; Mochizuki, M | 1 |
| Altamura, AC; Buoli, M; Serati, M | 1 |
| Ishigooka, J; Iwata, N; Nakagome, K; Ohmori, T | 1 |
| Datta, SS; Furtado, VA; Kumar, A; Russell, PS; Wright, SD | 1 |
| Cantisani, A; Ferrari, G; Grassi, G; Pallanti, S; Poli, L; Righi, L | 1 |
| Au, RW; Chiu, HF; Dickerson, F; Kreyenbuhl, J; Lai, KY; Man, D; Shum, D; Tang, WK; Ungvari, GS; Wang, CY; Xiang, YT; Yu, X; Zhou, FC; Zhou, JJ; Zhou, Y | 1 |
| Dore, J; Hill, SJ; Hooshmand, F; Ketter, TA; Miller, S; Portillo, N; Wang, PW | 1 |
| Buchanan, RW; Newcomer, JW; Weiden, PJ | 1 |
| Correll, CU; Iwata, N; Kishi, T; Matsuda, Y | 1 |
| Alva, G; Brams, M; Citrome, L; Glick, ID; Hochfeld, M; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Pestreich, L; Weiden, PJ; Winseck, A | 1 |
| Awad, G; Hassan, M; Hsu, J; Loebel, A; Pikalov, A; Rajagopalan, K | 1 |
| Chennoufi, L; Cheour, M; Ouanes, S | 1 |
| Bahramzi, M; Campillo, A; Minassian, A; Vilke, GM; Wilson, MP | 1 |
| Eleméry, M; Faludi, G; Kovács, G; Szegő, A | 1 |
| Aguglia, E; Bianchini, O; Cannavò, D; De Ronchi, D; Nespeca, C; Porcelli, S; Serretti, A; Trappoli, A | 1 |
| Brawman-Mintzer, O; Gros, DF; Hershenberg, R | 1 |
| Cichocki, M; Kus, K; Nowakowska, E; Ratajczak, P; Woźniak, A | 1 |
| Hu, JY; Huang, A; Liu, YY; Liu, ZL; Wang, LM; Wen, XJ | 1 |
| Pawelczyk, A; Pawelczyk, T; Rabe-Jablonska, J | 1 |
| Danielewicz, R; Herman, S; Kus, K; Nowakowska, E; Ratajczak, P; Woźniak, A | 1 |
| Morrissette, DA; Stahl, SM | 1 |
| Boettger, S; Breitbart, W; Jenewein, J | 1 |
| Eifler, S; Englisch, S; Esslinger, C; Kirsch, P; Meyer-Lindenberg, A; Mier, D; Rausch, F; Schirmbeck, F; Zink, M | 1 |
| Cornelius, V; Smith, L; Taylor, DM; Young, AH | 1 |
| Alva, G; Citrome, L; Glick, ID; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Weiden, PJ; Winseck, A | 1 |
| Aiello, R; Citraro, R; De Sarro, G; Leo, A; Pugliese, M; Russo, E | 1 |
| Ghezai, H; Goldacre, B; Hodsoll, J; Miles, S; Smallcombe, N; Veale, D | 1 |
| Chiu, HF; Dong, H; Han, X; Lu, Z; Ungvari, GS; Wang, CY; Wu, YF; Xiang, YT; Yang, FD; Yu, X; Yuan, YB; Zhao, JP | 1 |
| Crespo-Facorro, B; Prieto, C; Sainz, J | 1 |
| Damkier, P; Ennis, ZN | 1 |
| Deng, C; Han, M; Hu, CH; Huang, XF; Pan, B | 1 |
| Brown, JB; Kadoyama, K; Kimura, G; Miki, I; Nakamura, T; Nisiguchi, K; Okuno, Y; Sakaeda, T | 1 |
| Berardi, MA; Caraceni, A; Caruso, R; Grassi, L; Mitchell, AJ; Nanni, MG; Riba, M | 1 |
| Habata, Y; Imaichi, S; Komatsu, H; Maruyama, M; Mori, M; Sakuma, K | 1 |
| Connolly, JG; Schneeweiss, MC; Toomey, TJ | 1 |
| Brooks, KR; Kram, BL; Kram, SJ | 1 |
| Abbate-Daga, G; Amianto, F; Desedime, N; Fassino, S; Giovannone, C; Marzola, E | 1 |
| Cho, HY; Kim, YH; Lee, BJ; Lee, CH; Lee, JG; Park, SW; Seo, MK; You, YS | 1 |
| Alshehabi, E; Rickels, K; Rickels, MR; Teff, KL | 1 |
| Amada, N; Deiana, S; Kikuchi, T; Riedel, G; Stott, C; Watanabe, A; Yamasaki, Y | 1 |
| Al-Jadiri, A; Azzo, S; Carbon, M; Correll, CU; Kane, JM; Kapoor, S; Saito, E; Sarkaria, T; Sheridan, E | 1 |
| Bereza, BG; Einarson, TR; Goswami, P; Pudas, H; van Impe, K | 1 |
| De Santis, M; Deng, C; Huang, XF; Lian, J | 2 |
| Auricchio, F; Baldelli, S; Bernardini, R; Bertella, S; Bravaccio, C; Capuano, A; Carnovale, C; Cattaneo, D; Clementi, E; Ferrajolo, C; Fucile, S; Guastella, G; Mani, E; Molteni, M; Pascotto, A; Pisano, S; Pozzi, M; Radice, S; Rafaniello, C; Riccio, MP; Rizzo, R; Rossi, F; Scuderi, MG; Sperandeo, S; Sportiello, L; Villa, L | 1 |
| Beillat, M; Robinson, P; Sapin, C; Tempest, M; Treur, M | 1 |
| Khouzam, HR | 1 |
| Giermaziak, W; Kus, K; Nowakowska, E; Ratajczak, P | 1 |
| Baymeeva, NV; Burminskiy, DS; Miroshnichenko, II; Morozova, MA; Platova, AI; Potanin, SS | 1 |
| Bieńkowski, P; Jastrzębska-Więsek, M; Kołaczkowski, M; Mierzejewski, P; Partyka, A; Wasik, A; Wesołowska, A | 1 |
| Amato, L; Indave, BI; Minozzi, S; Pani, PP | 1 |
| Cordes, J; Gründer, G; Heinze, M; Mühlbauer, B; Rüther, E; Schulz, C; Timm, J | 1 |
| Uguz, F | 1 |
| Davis, JM; Furtado, VA; Hosalli, P; Sampson, S | 1 |
| Ake, T; Al-Dhaher, Z; Carbon, M; Correll, CU; David, L; Kane, JM; Kapoor, S; Krakower, S; Saito, E | 1 |
| Ariyawansa, J; De Meulder, M; Remmerie, B; Savitz, A | 1 |
| De Meulder, M; Remmerie, B; Savitz, A; Weiner, S | 1 |
| Deng, C; Lian, J; Pan, B | 2 |
| Gołembiowska, K; Kus, K; Nowakowska, E; Noworyta-Sokołowska, K; Ratajczak, P; Woźniak, A; Zaprutko, T | 1 |
| Chaichan, W; Kittipeerachon, M | 1 |
| Cocker, KE; Reese, TR; Thiel, DJ | 1 |
| Bruhn, CH; Hashemi, N; Nielsen, J; Polcwiartek, C; Rosenzweig, M; Vang, T | 1 |
| Alphs, L; Correll, CU; Kim, E; Mao, L; Starr, HL | 1 |
| Bergmans, P; Caspi, A; Cherubin, P; Hargarter, L; Keim, S; Lara, E; Pinchuk, I; Schreiner, A; Schuepbach, D; Suleman, S | 1 |
| Bervoets, C; Cleymans, S; Morrens, M | 1 |
| Li, Y; Wang, ST | 1 |
| Bleich, S; Frieling, H; Hilfiker-Kleiner, D; Kahl, KG; Kotsiari, A; Scherr, M; Stapel, B | 1 |
| Loebel, A; Meyer, N; Rajagopalan, K; Wade, S | 1 |
| Andersen, M; Bodén, R; Brandt, L; Kieler, H; Reutfors, J; Tanskanen, A; Tiihonen, J; Wingård, L | 1 |
| Crespo-Facorro, B; Gomez-Arnau, J; Juncal-Ruiz, M; Martinez-Garcia, O; Neergaard, KD; Ortiz-Garcia de la Foz, V; Ramirez-Bonilla, M; Suarez-Pinilla, P; Tabares-Seisdedos, R | 1 |
| Fujibayashi, M; Hattori, S; Hirayasu, Y; Ishii, C; Ishii, N; Kishida, I; Miyauchi, M; Moritani, T; Shiraishi, Y; Suda, A; Taguri, M; Tsujita, N | 2 |
| Baldelli, S; Bernardi, FF; Bernardini, R; Bravaccio, C; Capuano, A; Cattaneo, D; Cheli, S; Clementi, E; Molteni, M; Pozzi, M; Radice, S; Rafaniello, C; Rossi, F; Sessa, M | 1 |
| Mock, CK; Teslyar, P; Thom, RP | 1 |
| Chikama, K; Kajitani, K; Nakabeppu, Y; Tsukamoto, T; Uchimura, N; Yamada, H | 1 |
| Emond, B; Joshi, K; Kamstra, R; Lafeuille, MH; Lefebvre, P; Pilon, D; Tandon, N | 1 |
| Hashimoto, N; Kuksumi, I; Miyamoto, T; Miyazaki, A; Toyomaki, A | 1 |
| Dietrich-Muszalska, A; Kolińska-Łukaszuk, J | 1 |
| Jajawi, S; Jayaram, MB; Ostinelli, EG; Sayal, K; Spyridi, S | 1 |
| Zun, LS | 1 |
| Bramness, JG; Handal, M; Hartz, I; Hjellvik, V; Nesvåg, R; Skurtveit, S | 1 |
| Green, B; Korell, J; Rae, A; Remmerie, B; Vermeulen, A | 1 |
| Deng, C; Lian, J | 1 |
| Bateman, BT; Cohen, JM; Cohen, LS; Desai, RJ; Glynn, RJ; Hernandez-Diaz, S; Huybrechts, KF; Mogun, H; Park, Y; Patorno, E | 1 |
| Carvalho, AF; Hidalgo-Mazzei, D; Murru, A; Pacchiarotti, I; Samalin, L; Verdolini, N; Vieta, E; Young, AH | 1 |
| Matsuda, H; Mori, T; Okamoto, K; Ono, S; Ozeki, Y; Sagae, T; Shimoda, K; Someya, T; Sugai, T; Sugawara, N; Suzuki, Y; Yamazaki, M; Yasui-Furukori, N | 1 |
| Flavin, KS; Newcomer, JW; Nicol, GE; Patterson, BW; Schechtman, KB; Schweiger, JA; Yingling, MD | 1 |
| Dong, F; Ji, SM; Li, AN; Li, L; Lu, W; Wang, CY; Zhou, TY | 1 |
| Bleich, S; Falk, CS; Hilfiker-Kleiner, D; Kahl, KG; Sieve, I; Stapel, B | 1 |
| Dias Alves, M; Micoulaud-Franchi, JA; Simon, N; Vion-Dury, J | 1 |
| Adamopoulos, P; Budhrani, GS; Easton, GS; Gray, DW; Jabaley, CS; Lynde, GC; O'Reilly-Shah, VN | 1 |
| Cheng, Y; Jiang, K; Li, Q; Lin, Z; Xuan, J; Zhang, Y; Zhao, J | 1 |
| Li, P; Liu, X; Wang, J; Wang, Y; Yang, L; Zheng, L; Zhou, H; Zhou, Z | 1 |
| Belsham, DD; Hahn, MK; Kanagasundaram, P; Kowalchuk, C | 1 |
| Boland, X; Chhabra, P | 1 |
| Kiss, A; Koprdova, R; Osacka, J; Pecenak, J | 1 |
| Deckert, J; Menke, A; Scherf-Clavel, M; Unterecker, S; Weidner, A | 1 |
| Cope, N; Fowler, JC; Knights, J; Makin, A; Peters-Strickland, T; Phiri, P; Rathod, S | 1 |
| Huang, A; Loebel, A; Messali, A; Ng-Mak, D; Wang, L | 1 |
| He, S; Li, HF; Li, Y; Li, YG; Qiao, Y; Shen, YF; Wen, H; Yu, YM; Zhang, L; Zhang, Y | 1 |
| Belsham, DD; Hahn, MK; Kanagasundaram, P; Kowalchuk, C; McIntyre, WB | 1 |
| Cai, S; Cheng, Z; Correll, CU; Deng, H; Han, X; Lu, Z; Wang, C; Xiang, Y; Yang, F; Yang, L; Yu, X; Yuan, Y; Zhao, J | 1 |
| Iyer, S; Joober, R; Lepage, M; Malla, A; Mustafa, S; Shah, J | 1 |
| Kiss, A; Osacka, J | 4 |
| Almby, KE; Di Nunzio, G; Eriksson, JW; Lundqvist, M; Marques-Santos, CM; Pereira, MJ; Sarsenbayeva, A; Thombare, K | 1 |
| Kishi, Y; Kono, T; Minao, N; Mitsui, S; Obayashi, Y; Okahisa, Y; Sakamoto, S; Takaki, M; Takao, S; Takeda, T; Yada, Y; Yamada, N; Yoshimura, B | 1 |
| Garel, N; Joober, R | 1 |
| Bai, Y; Chen, G; Gao, K; Yang, H | 1 |
| Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S | 1 |
| Broder, MS; Chang, E; Greene, M; Houle, CR; Tarbox, MH; Waters, HC; Yan, T | 1 |
| Kopciuch, D; Kus, K; Murawiecka, P; Nowakowska, E; Paczkowska, A; Ratajczak, P; Słodzińska, I; Zaprutko, T | 1 |
| Ayesa-Arriola, R; Crespo-Facorro, B; Gómez-Revuelta, M; Juncal-Ruiz, M; Pelayo-Terán, JM; Romero-Jiménez, R; Setién Suero, E; Suárez-Pinilla, P; Vázquez-Bourgon, J | 1 |
| Jovanović, M; Miljković, B; Vučićević, K | 1 |
| Chen, Q; Coid, J; Deng, W; Guo, W; Hu, X; Li, K; Li, L; Li, T; Li, X; Li, Y; Lu, T; Lv, L; Ma, X; Ren, H; Reynolds, GP; Tan, L; Tan, Q; Tian, Y; Wang, C; Wang, H; Wang, L; Wang, Q; Wei, W; Yan, H; Yang, F; Yang, G; Yang, J; Yu, H; Yue, W; Zhang, D; Zhang, F; Zhang, H; Zhang, Y; Zhao, L | 1 |
| Abad-Santos, F; Almenara, S; de Miguel-Cáceres, A; Koller, D; Martín, S; Mejía, G; Navares-Gómez, M; Ochoa, D; Román, M; Romero-Palacián, D; Saiz-Rodríguez, M; Wojnicz, A; Zubiaur, P | 1 |
| Le, J; Li, Y; Wang, S; Yuan, T | 1 |
| Escudero, MAG; Gutiérrez-Rojas, L; Lahera, G | 1 |
| Lin, Z; Xuan, J | 1 |
| Claro, A; Corte-Real, F; Franco, J; Monteiro, C; Mustra, C; Proença, P | 1 |
| Abad-Santos, F; Almenara, S; Koller, D; Martín, S; Mejía, G; Navares-Gómez, M; Ochoa, D; Román, M; Romero-Palacián, D; Saiz-Rodríguez, M; Wojnicz, A; Zubiaur, P | 1 |
| Davis, JM; Leucht, S | 1 |
| Alisauskiene, R; Anda, LG; Bartz-Johannessen, C; Berle, JØ; Bjarke, J; Fathian, F; Fleischhacker, WW; Hugdahl, K; Joa, I; Johnsen, E; Kjelby, E; Kroken, RA; Larsen, TK; Løberg, EM; Reitan, SK; Rettenbacher, M; Sinkeviciute, I; Skrede, S; Stabell, L; Steen, VM; Walla, B | 1 |
| Abad-Santos, F; Almenara, S; Koller, D; Mejía, G; Navares-Gómez, M; Ochoa, D; Pintos-Sánchez, E; Román, M; Saiz-Rodríguez, M; Santos-Molina, E; Zubiaur, P | 1 |
| Chen, A; Cloutier, A; Copeli, F; Metzger, E; Osser, DN | 1 |
| Likhitsathian, S; Maneeton, B; Maneeton, N; Oon-Arom, A; Srisurapanont, M; Suradom, C; Suttajit, S | 1 |
| Baandrup, L; Ebdrup, BH | 1 |
| Johnsen, E; Kroken, RA; Steen, VM | 1 |
| Hadryś, T; Rymaszewska, J | 1 |
| Barbui, C; Bertolini, F; Bovo, C; Correll, CU; Del Giovane, C; Gastaldon, C; Nosé, M; Ogheri, F; Ostuzzi, G; Papola, D; Purgato, M; Tedeschi, F; Turrini, G | 1 |
| Aronen, ET; Mogk, H; Rättö, H; Saastamoinen, LK; Varimo, E | 1 |
| Dar, SA; Haq, I; Wani, RA | 1 |
| Artunduaga, JC; Coffey, BJ; Kufert, Y; Mor, M | 1 |
| Kyriakopoulos, M; Singappuli, P; Sonuga-Barke, E | 1 |
| Kyziridis, TC | 1 |
| Baldessarini, RJ; Gaudiot, CES; Nestsiarovich, A; Tohen, M; Vieta, E; Zhu, Y | 1 |
| Abler, V; Rajagopalan, K; Rashid, N; Yunusa, I | 1 |
| Alda, M; Beaulieu, S; Berk, M; Bond, DJ; Calabrese, J; Chakrabarty, T; Frey, BN; Goldstein, BI; Kanba, S; Kapczinski, F; Kauer-Sant'Anna, M; Kennedy, SH; Kozicky, JM; Lam, RW; Malhi, G; McIntyre, RS; Milev, RV; O'Donovan, C; Parikh, SV; Post, R; Ravindran, AV; Rej, S; Schaffer, A; Sharma, V; Suppes, T; Tourjman, V; Vazquez, G; Vieta, E; Yatham, LN | 1 |
| Hatano, M; Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Nomura, I; Okuya, M; Sakuma, K | 1 |
| Heng, W; Wu, G; Zang, X; Zhu, L | 1 |
| Abad-Santos, F; Cigudosa, JC; Ferreira, V; Grajales, D; Hitos, AB; Koller, D; Leibowitz, G; Mirasierra, M; Quesada, I; Ruíz-Rosario, M; Tirosh, B; Tudurí, E; Vallejo, M; Valverde, ÁM; Vázquez, P; Zubiaur, P | 1 |
| Abler, VC; Demos, GN; Mahadik, BS; Rajagopalan, K; Rashid, N; Yunusa, I | 1 |
| Biederman, J; Cook, E; DiSalvo, M; Faraone, SV; Farrell, A; Joshi, G; Wozniak, J; Yule, A | 1 |
| Roosen, L; Sienaert, P | 1 |
| De Ponti, F; Fusaroli, M; Giunchi, V; Menchetti, M; Poluzzi, E; Raschi, E; Rimondini Giorgini, R | 1 |
| Choi, SY; Jang, S; Kim, DG; Kim, J; Kim, S; Lee, CH; Lee, KW; Lee, N; Park, JK; Suh, SB | 1 |
| Byeon, SJ; Chung, SJ; Oh, S | 1 |
| Johannesen, CAB; Johnsen, E; Kroken, RA; Larsen, TK; Løberg, EM; Mørkved, N; Rettenbacher, MA; Thimm, JC; Winje, D | 1 |
| Osman, E; Yıldız, M | 1 |
| Chiappini, S; Giannantonio, MD; Martinotti, G; Miuli, A; Mosca, A; Pettorruso, M; Santovito, MC; Sensi, SL; Skryabin, V | 1 |
| Arango, C; Leucht, S; Lopez-Morinigo, JD | 1 |
| Jauhar, S; Kaufman, KR; Kerr-Gaffney, J; Kurana, S; Strawbridge, R; Yalin, N; Young, AH | 1 |
| Berk, M; Bortolasci, CC; Dean, OM; Gray, L; Kidnapillai, S; Kim, JH; Liu, ZSJ; McGee, SL; Panizzutti, B; Richardson, MF; Spolding, B; Swinton, C; Truong, TTT; Walder, K | 1 |
| Kramar, B; Milisav, I; Monsalve, M; Pirc Marolt, T; Šuput, D | 1 |
| Chen, B; Ma, X; Wang, M; Yan, Y; Yang, X; Yin, L | 1 |
| Bleacher, H; DeSanto, K; Koerperich, L; Malam, N | 1 |
| Deng, C; Han, M; Hodgson, J; Lian, J; Su, Y | 1 |
| Cao, D; Hong, Y; Huang, W; Wang, L; Wei, H; Xu, J; Zhang, J | 1 |
| Alexinschi, O; Carvalho, AF; Cavaliere, L; Correll, CU; Cortese, S; Croatto, G; Fiedorowicz, JG; Firth, J; Fusar-Poli, P; Gaina, MA; Makkai, V; Miola, A; Olivola, M; Shin, JI; Soares, FC; Solmi, M; Stubbs, B; Vancampfort, D; Vianello, G; Vieta, E | 1 |
| Cao, L; Liu, J; Wu, J | 1 |
| Hu, J; Huang, S; Shang, D; Wen, Y; Xiao, T; Zhu, X | 1 |
| Chen, Q; Deng, W; Du, X; Hao, Q; Hu, X; Li, C; Li, K; Li, L; Li, T; Li, X; Lu, T; Lv, L; Ma, X; Ren, H; Tan, L; Tan, Q; Tang, Y; Wang, C; Wang, L; Wang, Q; Wang, Y; Wu, Y; Yan, H; Yang, F; Yang, G; Yang, J; Yu, H; Yue, W; Zhang, D; Zhang, F; Zhang, G; Zhang, H; Zhang, Y; Zhao, L | 1 |
| Ahmed, F; Eriksson, JW; Fanni, G; Ferreira, V; Hetty, S; Pereira, MJ; Sarsenbayeva, A; Valverde, ÁM; Vranic, M | 1 |
| Carvalho, AF; Hsu, CW; Hsu, TW; Liang, CS; Thompson, T; Tsai, TC; Tseng, PT; Yu, CL | 1 |
| Gupta, B; Lee, J; Pilunthanakul, T; Ting, MQJ | 1 |
| Cai, J; Gao, M; Huang, J; Huang, Y; Kang, D; Li, L; Liu, F; Long, Y; Ou, J; Peng, X; Shao, P; Shao, T; Shen, Y; Song, C; Su, Y; Sun, M; Wang, W; Wang, X; Wu, Q; Wu, R; Xiao, J; Xie, P; Yang, Y | 1 |
| Blanchet, C; Carretier, E; Guessoum, SB; Ludot, M; Moro, MR; Thorey, S | 1 |
| Carlson, HE; Correll, CU; Kazimi, MM; Koch, MT | 1 |
| Cheng, Z; Gao, T; Huang, B; Huang, Z; Pu, C; Shi, C; Yu, X; Zhang, D; Zheng, Y; Zhou, E; Zhou, T | 1 |
| Feng, X; Kang, Z; Liao, Y; Lu, T; Lu, Z; Sun, Y; Wang, L; Yan, H; Yue, W; Zhang, D; Zhang, Y | 1 |
| Breen, G; Everall, I; Guo, LK; Huang, HL; Huang, Z; Kang, ZW; Li, J; Li, M; Li, WQ; Li, Y; Liao, YD; Liu, B; Lu, TL; Lu, Z; Lv, LX; Su, Y; Tan, YL; Wang, HX; Wang, LF; Xiao, X; Yan, H; Yang, YF; Yao, Y; Yu, H; Yue, WH; Zhang, D; Zhang, YY | 1 |
| Blindheim, A; Gjestad, R; Joa, I; Johnsen, E; Kroken, RA; Løberg, EM; Munk-Jørgensen, P; Reitan, SK; Rettenbacher, M; Stabell, LA | 1 |
| Harada, T; Hosokawa, T; Kishi, Y; Miyaji, C; Nomura, A; Okahisa, Y; Sakamoto, S; Takaki, M; Takao, S; Takeda, T; Washida, K; Yada, Y; Yamada, N; Yoshimura, Y | 1 |
| Cai, J; Chen, Y; Fang, M; Hu, J; Huang, M; Liu, F; Liu, T; Liu, Z; Long, Y; Meng, H; Song, X; Tang, Y; Wan, C; Wang, X; Wang, Z; Wu, Q; Wu, R; Wu, X; Xiao, J; Xu, X; Xu, Y; Yang, Y; Zhang, R; Zhao, J; Zheng, Y | 1 |
| Apa, H; Kutlu, A; Songür, ÇY | 1 |
| Benites-Zapata, VA; Campos-Rodriguez, SK; Fernández, MF; Ortiz-Saavedra, B; Pino-Zavaleta, DA; Valdivieso-Jiménez, G | 1 |
| Li, M; Li, W; Qiu, Z; Wang, J; Wu, H | 1 |
| Buckle, J; Forshall, E; Harris, M; Kavanagh, G; Murphy, T; Pereira, M; Thompson, A; Whale, R; Wilson, M | 1 |
112 review(s) available for aripiprazole and olanzapine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dosage Forms; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2002 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Therapeutic Equivalency; Thiazoles | 2003 |
Antipsychotic medication and seizures: a review.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Risperidone; Seizures; Thiazoles | 2003 |
Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Patient Compliance; Piperazines; Polypharmacy; Quetiapine Fumarate; Quinolones; Research Design; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2004 |
Efficacy of atypical antipsychotics in elderly patients with dementia.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Rating Scale; Controlled Clinical Trials as Topic; Dementia; Dibenzothiazepines; Humans; Mental Disorders; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Treatment Outcome | 2004 |
[Psychotropics and weight gain].
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Child; Clozapine; Dibenzothiazepines; Double-Blind Method; Female; Fructose; Haloperidol; Humans; Imidazoles; Indoles; Male; Obesity; Olanzapine; Piperazines; Placebos; Psychotropic Drugs; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Socioeconomic Factors; Sulpiride; Thiazoles; Time Factors; Topiramate; Valproic Acid; Weight Gain | 2004 |
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Administration Schedule; Humans; Hyperprolactinemia; Mental Disorders; Olanzapine; Patient Compliance; Piperazines; Practice Guidelines as Topic; Prescription Fees; Quetiapine Fumarate; Quinolones; Risk Assessment; Risperidone; Thiazoles; Torsades de Pointes; Treatment Outcome; Weight Gain | 2004 |
Pharmacology of antipsychotics in the elderly: a focus on atypicals.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Serotonin Antagonists; Thiazoles; Treatment Outcome; United States | 2004 |
Optimizing atypical antipsychotic treatment strategies in the elderly.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dementia; Dibenzothiazepines; Humans; Olanzapine; Parkinson Disease; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome | 2004 |
The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania.
Topics: Acute Disease; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disorder; Clozapine; Dibenzothiazepines; Double-Blind Method; Humans; Lithium; Olanzapine; Piperazines; Placebos; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Treatment Outcome | 2005 |
The treatment of mixed states and the risk of switching to depression.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Electroconvulsive Therapy; Haloperidol; Health Education; Humans; Lithium Carbonate; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Thiazoles | 2005 |
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Cardiomyopathies; Child; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Drug Interactions; Drug Overdose; Dry Eye Syndromes; Humans; Hyperlipidemias; Hypotension; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Seizures; Thiazoles | 2005 |
A typical mood stabilizers: a "typical role for atypical antipsychotics.
Topics: Affect; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Clozapine; Dibenzothiazepines; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Secondary Prevention; Sulpiride; Thiazoles | 2005 |
Antipsychotic poisoning in young children: a systematic review.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Chlorpromazine; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Infant; Infant, Newborn; Olanzapine; Pimozide; Piperazines; Poisoning; Quetiapine Fumarate; Quinolones; Risperidone | 2005 |
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Dyskinesia, Drug-Induced; Humans; Incidence; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2005 |
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Topics: Aggression; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Humans; Mental Disorders; Olanzapine; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone | 2006 |
Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dementia; Dibenzothiazepines; Double-Blind Method; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic | 2006 |
Haloperidol alone or in combination for acute mania.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepine; Dibenzothiazepines; Drug Therapy, Combination; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Sulpiride; Valproic Acid | 2006 |
Long-term use of atypical antipsychotics in bipolar disorder.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug Administration Schedule; Drug Costs; Humans; Olanzapine; Piperazines; Practice Guidelines as Topic; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Thiazoles; United States | 2006 |
Maintenance treatment of bipolar disorder: Applying research to clinical practice.
Topics: Anticonvulsants; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepine; Evidence-Based Medicine; Humans; Lamotrigine; Lithium Carbonate; Olanzapine; Piperazines; Quinolones; Triazines; Valproic Acid | 2006 |
Treatment of psychosis: 30 years of progress.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Thiazoles | 2006 |
[The use of atypical antipsychotics in the long-term care of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Cognition Disorders; Drug Tolerance; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Sulpiride; Time Factors | 2006 |
Metabolic effects of the atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dyslipidemias; Glucose Metabolism Disorders; Humans; Insulin Resistance; Mental Disorders; Obesity; Olanzapine; Phenothiazines; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2007 |
Managing the acutely agitated and psychotic patient.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Emergencies; Humans; Olanzapine; Piperazines; Psychomotor Agitation; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2007 |
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Bipolar Disorder; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome; Weight Gain | 2007 |
Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Diabetes Mellitus, Type 2; Humans; Olanzapine; Piperazines; Quinolones; Schizophrenia | 2007 |
Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Humans; Injections, Intramuscular; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Treatment Outcome | 2007 |
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Drug Resistance; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Serotonin 5-HT2 Receptor Antagonists; Thiazoles; Trazodone; Triazoles | 2008 |
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Double-Blind Method; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Research Design; Risperidone; Schizophrenia; Sleep Stages; Thiazoles; Treatment Outcome | 2008 |
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Child; Dibenzothiazepines; Disorders of Excessive Somnolence; Headache; Humans; Methylphenidate; Obesity; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone | 2008 |
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.
Topics: Adolescent; Aggression; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Benzodiazepines; Child; Child Development Disorders, Pervasive; Child, Preschool; Clozapine; Dibenzothiazepines; Disorders of Excessive Somnolence; Humans; Obesity; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles | 2008 |
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Diseases; Child; Chronic Disease; Clozapine; Comorbidity; Disease Progression; Humans; Magnetic Resonance Imaging; Olanzapine; Piperazines; Prognosis; Psychotic Disorders; Quinolones; Schizophrenia; Thiazoles; Treatment Failure | 2008 |
Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Child; Child, Preschool; Clozapine; Dibenzothiazepines; Humans; Neuroleptic Malignant Syndrome; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Thiazoles | 2008 |
A clinical paradigm of delusions of parasitosis.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Diagnosis, Differential; Female; Humans; Metabolic Syndrome; Middle Aged; Olanzapine; Pain; Patient Compliance; Peripheral Nervous System Diseases; Piperazines; Quinolones; Schizophrenia, Paranoid; Skin Diseases, Parasitic; Sleep Wake Disorders | 2008 |
[The use of antipsychotics in patients with dementia].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cerebrovascular Disorders; Dementia; Dementia, Vascular; Dibenzothiazepines; Double-Blind Method; Evidence-Based Medicine; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Treatment Outcome | 2008 |
Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cholesterol; Cholesterol, HDL; Endpoint Determination; Female; Humans; Lipoproteins; Male; Multicenter Studies as Topic; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome; Triglycerides | 2008 |
How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins.
Topics: Adiponectin; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Diabetes Mellitus; Humans; Leptin; Obesity; Olanzapine; Piperazines; Quinolones; Receptor, Muscarinic M3; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Receptors, Histamine; Serotonin 5-HT1 Receptor Agonists; Thiazoles; Weight Gain | 2009 |
Akathisia and second-generation antipsychotic drugs.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Prevalence; Psychomotor Agitation; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Risperidone; Sulpiride; Thiazoles | 2009 |
A systematic review of cardiovascular effects after atypical antipsychotic medication overdose.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cardiovascular System; Dibenzothiazepines; Drug Overdose; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles | 2009 |
Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug Combinations; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Piperazines; Placebos; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Aripiprazole versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2009 |
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Haloperidol; Humans; Hypnotics and Sedatives; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Olanzapine versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sulpiride; Thiazoles | 2010 |
Antipsychotics in pregnancy.
Topics: Abnormalities, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes, Gestational; Dibenzothiazepines; Female; Humans; Infant, Newborn; Olanzapine; Piperazines; Pregnancy; Pregnancy Complications; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles | 2010 |
Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Biostatistics; Clinical Trials as Topic; Depressive Disorder, Major; Dibenzothiazepines; Drug Combinations; Drug Therapy, Combination; Epidemiologic Measurements; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones | 2010 |
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Weight Gain | 2010 |
Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.
Topics: Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Drug Resistance; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Selective Serotonin Reuptake Inhibitors; Thiazoles | 2010 |
Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Evidence-Based Medicine; Female; Humans; Male; Multicenter Studies as Topic; Olanzapine; Patient Selection; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Second-generation antipsychotics in major depressive disorder: update and clinical perspective.
Topics: Adult; Amisulpride; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Drug Therapy, Combination; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Sulpiride | 2011 |
Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Child; Humans; Olanzapine; Piperazines; Practice Guidelines as Topic; Quinolones; Risperidone; Treatment Outcome | 2011 |
Switching and combining antipsychotics.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Decision Making; Female; Humans; Olanzapine; Piperazines; Polypharmacy; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Weight Gain | 2010 |
Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Dibenzothiazepines; Drug Substitution; Fasting; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Schizophrenia; Weight Gain | 2010 |
Second-generation antipsychotics for major depressive disorder and dysthymia.
Topics: Amisulpride; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Dysthymic Disorder; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Sulpiride | 2010 |
Risperidone versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Thiazoles | 2011 |
[Augmentation of antidepressants with atypical antipsychotics in non-delusional unipolar depressed patients with non-response to antidepressant-monotherapy].
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Treatment-Resistant; Dibenzothiazepines; Double-Blind Method; Drug Therapy, Combination; Humans; Lithium Carbonate; Olanzapine; Patient Compliance; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone | 2012 |
Age-grouped differences in bipolar mania.
Topics: Adolescent; Adult; Age Factors; Aggression; Anger; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Bipolar Disorder; Child; Clinical Trials as Topic; Comorbidity; Defense Mechanisms; Female; Humans; Irritable Mood; Male; Middle Aged; Motor Activity; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychometrics; Quinolones; Sexual Behavior; Thinking; Young Adult | 2012 |
Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Depression; Depressive Disorder; Dibenzothiazepines; Double-Blind Method; Drug Industry; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Research Support as Topic; Risperidone; Thiazoles | 2013 |
Atypical antipsychotics for the treatment of disruptive behavior.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Child; Clozapine; Dibenzothiazepines; Drug Interactions; Drug Monitoring; Humans; Olanzapine; Pediatrics; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone | 2013 |
Aripiprazole versus other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles | 2013 |
[Pharmacological treatment of delirium in palliative care patients. A systematic literature review].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Delirium; Evidence-Based Medicine; Haloperidol; Humans; Hypnotics and Sedatives; Lorazepam; Olanzapine; Palliative Care; Piperazines; Quinolones; Risk Factors | 2013 |
Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Humans; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Weight Gain | 2013 |
Is the combination of a mood stabilizer plus an antipsychotic more effective than mono-therapies in long-term treatment of bipolar disorder? A systematic review.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug Therapy, Combination; Humans; Long-Term Care; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome | 2014 |
Atypical antipsychotics for psychosis in adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Molindone; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2013 |
Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Drug Substitution; Dyskinesia, Drug-Induced; Evidence-Based Medicine; Humans; Lipids; Olanzapine; Patient Outcome Assessment; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology | 2013 |
Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials.
Topics: Amphetamine-Related Disorders; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Central Nervous System Stimulants; Cocaine; Cocaine-Related Disorders; Dopamine; Dopamine Uptake Inhibitors; Humans; Methamphetamine; Olanzapine; Outcome Assessment, Health Care; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Substance Withdrawal Syndrome; Synaptic Transmission; Treatment Outcome | 2013 |
An update on the treatment of mixed bipolar states: what is new in 2013?
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Calcitonin; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome | 2014 |
Role of atypical antipsychotics in the treatment of generalized anxiety disorder.
Topics: Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Generalization, Psychological; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Treatment Outcome | 2014 |
Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chemotherapy, Adjuvant; Depressive Disorder, Major; Dibenzothiazepines; Double-Blind Method; Drug Synergism; Humans; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Remission Induction; Risperidone; Treatment Outcome; Young Adult | 2014 |
Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Dibenzocycloheptenes; Drug Therapy, Combination; Heterocyclic Compounds, 4 or More Rings; Humans; Impulsive Behavior; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Polypharmacy; Psychotic Disorders; Quetiapine Fumarate; Receptors, Dopamine D2; Risperidone; Thiazoles; Violence | 2014 |
Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Depression; Dibenzothiazepines; Drug Therapy, Combination; Fluoxetine; Humans; Isoindoles; Lamotrigine; Lithium Compounds; Lurasidone Hydrochloride; Monoamine Oxidase Inhibitors; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Selective Serotonin Reuptake Inhibitors; Thiazoles; Treatment Outcome; Triazines; Valproic Acid | 2014 |
Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clomipramine; Dibenzothiazepines; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Humans; Obsessive-Compulsive Disorder; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2014 |
Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review.
Topics: Abnormalities, Drug-Induced; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Humans; Olanzapine; Pregnancy; Pregnancy Complications; Quetiapine Fumarate; Risperidone; Schizophrenia | 2015 |
Management of delirium in palliative care: a review.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cholinesterase Inhibitors; Delirium; Disease Management; Haloperidol; Health Personnel; Humans; Olanzapine; Palliative Care; Quetiapine Fumarate; Risperidone | 2015 |
Psychopharmacology of chronic pain: a focus on antidepressants and atypical antipsychotics.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bupropion; Chronic Pain; Humans; Mianserin; Mirtazapine; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Thiazoles; Trazodone; Triazoles | 2016 |
Antipsychotic medications for cocaine dependence.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cocaine-Related Disorders; Haloperidol; Humans; Lamotrigine; Olanzapine; Patient Dropouts; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Reserpine; Risperidone; Triazines | 2016 |
Second-Generation Antipsychotics During the Lactation Period: A Comparative Systematic Review on Infant Safety.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Breast Feeding; Female; Humans; Infant Health; Infant, Newborn; Lactation; Olanzapine; Prospective Studies; Risperidone | 2016 |
Risperidone (depot) for schizophrenia.
Topics: Administration, Oral; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Delayed-Action Preparations; Humans; Olanzapine; Patient Dropouts; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2016 |
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Basal Ganglia Diseases; Behavior Therapy; Benzodiazepines; Cognitive Behavioral Therapy; Dementia; Emotions; Humans; Hypotension, Orthostatic; Metabolic Syndrome; Neuroleptic Malignant Syndrome; Olanzapine; Practice Guidelines as Topic; Psychotic Disorders; Quetiapine Fumarate; Risperidone | 2016 |
Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Denmark; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Olanzapine; Risk Factors; Risperidone; Young Adult | 2016 |
Delirium in hospitalized patients: Risks and benefits of antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Delirium; Haloperidol; Hospitalization; Humans; Olanzapine; Quetiapine Fumarate; Risperidone | 2017 |
Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation).
Topics: Aggression; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Injections, Intramuscular; Olanzapine; Psychomotor Agitation; Randomized Controlled Trials as Topic; Tranquilizing Agents | 2018 |
Evidence-Based Review of Pharmacotherapy for Acute Agitation. Part 1: Onset of Efficacy.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Therapy; Evidence-Based Practice; Haloperidol; Humans; Injections, Intramuscular; Olanzapine; Psychomotor Agitation | 2018 |
Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy, Combination; Electroconvulsive Therapy; Humans; Lithium; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Practice Guidelines as Topic; Quetiapine Fumarate; Thiazoles; Valproic Acid | 2018 |
Do Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics?
Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Bipolar Disorder; Female; Humans; North America; Olanzapine; Quetiapine Fumarate; Risperidone; United States; Weight Gain | 2020 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes | 2020 |
Understanding variability in the pharmacokinetics of atypical antipsychotics - focus on clozapine, olanzapine and aripiprazole population models.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Models, Biological; Nonlinear Dynamics; Olanzapine | 2020 |
Second Generation Antipsychotics Monotherapy as Maintenance Treatment for Bipolar Disorder: a Systematic Review of Long-Term Studies.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Humans; Olanzapine; Quetiapine Fumarate; Risperidone | 2020 |
The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia.
Topics: Academic Medical Centers; Aged; Algorithms; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Citalopram; Dementia; Electroconvulsive Therapy; Haloperidol; Humans; Olanzapine; Psychopharmacology; Risperidone | 2021 |
Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Methamphetamine; Network Meta-Analysis; Olanzapine; Patient Dropouts; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia | 2021 |
Amisulpride - is it as all other medicines or is it different? An update.
Topics: Administration, Oral; Amisulpride; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Humans; Neurosecretory Systems; Olanzapine; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Schizophrenic Psychology | 2020 |
Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.
Topics: Antipsychotic Agents; Aripiprazole; Clopenthixol; Delayed-Action Preparations; Flupenthixol; Fluphenazine; Haloperidol; Humans; Injections, Intramuscular; Network Meta-Analysis; Olanzapine; Paliperidone Palmitate; Patient Acceptance of Health Care; Phenothiazines; Psychotic Disorders; Risperidone; Schizophrenia; Secondary Prevention | 2021 |
Antipsychotic long-term treatment in children and young people: a systematic review and meta-analysis of efficacy and tolerability across mental health and neurodevelopmental conditions.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Humans; Mental Health; Olanzapine; Prolactin; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2022 |
[Clinical pharmacokinetics and pharmaceutical forms of long-acting injectable antipsychotics].
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Olanzapine; Paliperidone Palmitate; Risperidone | 2022 |
Preventing new episodes of bipolar disorder in adults: Systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Lithium; Olanzapine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone | 2022 |
Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review.
Topics: Antipsychotic Agents; Aripiprazole; Dementia; Humans; Olanzapine; Psychotic Disorders; Risperidone | 2021 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations.
Topics: Antipsychotic Agents; Anxiety; Aripiprazole; Bipolar Disorder; Canada; Humans; Olanzapine; Valproic Acid | 2021 |
Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepine; Female; Haloperidol; Humans; Lithium; Male; Mania; Network Meta-Analysis; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Tamoxifen; Valproic Acid | 2022 |
Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dementia; Humans; Network Meta-Analysis; Off-Label Use; Olanzapine; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Treatment Outcome | 2022 |
Evidence-based treatment strategies for rapid cycling bipolar disorder, a systematic review.
Topics: Anticonvulsants; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Lamotrigine; Olanzapine; Quetiapine Fumarate; Valproic Acid | 2022 |
Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical Practice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Female; Humans; Male; Mice; Olanzapine; Quetiapine Fumarate; Rats; Risperidone | 2022 |
Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Haloperidol; Humans; Lurasidone Hydrochloride; Molindone; Olanzapine; Paliperidone Palmitate; Quality of Life; Quetiapine Fumarate; Risperidone; Schizophrenia; Systematic Reviews as Topic | 2022 |
A systematic review and meta-analysis of treatments for rapid cycling bipolar disorder.
Topics: Aripiprazole; Bipolar Disorder; Citalopram; Fluoxetine; Humans; Lamotrigine; Olanzapine; Quetiapine Fumarate; Venlafaxine Hydrochloride | 2022 |
Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Network Meta-Analysis; Olanzapine; Quetiapine Fumarate; Risperidone | 2022 |
Are antipsychotics effective adjunctive Tx for patients with moderate-to-severe depression?
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depression; Humans; Olanzapine; Quetiapine Fumarate | 2022 |
A cumulative Bayesian network meta-analysis on the comparative efficacy of pharmacotherapies for mania over the last 40 years.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Carbamazepine; Dibenzocycloheptenes; Haloperidol; Humans; Lithium; Mania; Network Meta-Analysis; Olanzapine; Paliperidone Palmitate; Pharmaceutical Preparations; Piperazines; Quetiapine Fumarate; Risperidone; Tamoxifen; Thiazoles; Valproic Acid | 2022 |
The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: An umbrella review of the evidence from randomised controlled trials.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Fluoxetine; Glycated Hemoglobin; Humans; Longevity; Olanzapine; Outcome Assessment, Health Care; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2023 |
Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China.
Topics: Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Humans; Lurasidone Hydrochloride; Olanzapine; Risperidone; Schizophrenia | 2022 |
Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Haloperidol; Humans; Mania; Olanzapine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2023 |
Efficacy and tolerance of second-generation antipsychotics in anorexia nervosa: A systematic scoping review.
Topics: Adolescent; Adult; Anorexia Nervosa; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone | 2023 |
Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review.
Topics: Adult; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Borderline Personality Disorder; Female; Humans; Male; Olanzapine | 2023 |
Comparative efficacy and safety of 4 atypical antipsychotics augmentation treatment for major depressive disorder in adults: A systematic review and network meta-analysis.
Topics: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Network Meta-Analysis; Olanzapine; Quetiapine Fumarate | 2023 |
49 trial(s) available for aripiprazole and olanzapine
| Article | Year |
|---|---|
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Female; Humans; Hyperlipidemias; Incidence; Lipids; Male; Obesity; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome; Weight Gain | 2004 |
The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Cognition; Female; Humans; Learning; Male; Memory; Middle Aged; Olanzapine; Piperazines; Quinolones | 2006 |
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Quinolones; Recurrence; Schizophrenia; Treatment Outcome; Triglycerides | 2006 |
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibenzothiazepines; Dose-Response Relationship, Drug; Europe; Female; Humans; Male; Middle Aged; Obesity; Olanzapine; Piperazines; Quality of Life; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Self Concept; Social Adjustment | 2008 |
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Obesity; Olanzapine; Overweight; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Triglycerides | 2008 |
A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Double-Blind Method; Electrocardiography; Female; Glucose; Humans; Lipid Metabolism; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Quinolones; Schizophrenia | 2009 |
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Dopamine Antagonists; Double-Blind Method; Female; Hospitalization; Humans; Lorazepam; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome; Triglycerides; United States; Young Adult | 2008 |
Results of phase 3 of the CATIE schizophrenia trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Clozapine; Dibenzothiazepines; Female; Hospitalization; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Treatment Outcome; Young Adult | 2009 |
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Olanzapine; Piperazines; Prolactin; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Sex Factors; Substance Withdrawal Syndrome; Young Adult | 2009 |
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; Olanzapine; Patient Satisfaction; Piperazines; Prolactin; Quality of Life; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Sexual Behavior; Treatment Outcome | 2008 |
A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.
Topics: Adult; Affect; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Olanzapine; Piperazines; Quinolones; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires | 2009 |
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; C-Reactive Protein; Cholesterol; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Glucose; Humans; Male; Middle Aged; Obesity; Olanzapine; Overweight; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Triglycerides | 2009 |
An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Attention; Benzodiazepines; Chronic Disease; Cognition Disorders; Dose-Response Relationship, Drug; Drug Substitution; Executive Function; Female; Humans; Isoindoles; Longitudinal Studies; Male; Memory; Middle Aged; Neuropsychological Tests; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Single-Blind Method; Thiazoles; Time Factors; Verbal Learning | 2011 |
Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression.
Topics: Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug Therapy, Combination; Fluoxetine; Humans; Lamotrigine; Olanzapine; Piperazines; Predictive Value of Tests; Psychiatric Status Rating Scales; Quetiapine Fumarate; Quinolones; Remission Induction; Sensitivity and Specificity; Time Factors; Treatment Outcome; Triazines | 2011 |
Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controll
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Drug Monitoring; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Thiazoles; Time Factors; Triglycerides; Weight Gain | 2010 |
The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Italy; Logistic Models; Olanzapine; Patient Selection; Piperazines; Proportional Hazards Models; Quinolones; Research Design; Schizophrenia; Time Factors | 2011 |
Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Olanzapine; Piperazines; Quinolones; Receptors, Dopamine D2; Risperidone; Schizophrenia | 2012 |
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Cholesterol; Cholesterol, LDL; Combined Modality Therapy; Dibenzothiazepines; Diet, Reducing; Drug Substitution; Exercise; Humans; Hypercholesterolemia; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk; Risperidone; Schizophrenia; Treatment Outcome; Triglycerides | 2011 |
Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from India.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Female; Humans; India; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Young Adult | 2013 |
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Therapeutic Equipoise; Triglycerides; United States | 2013 |
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Coronary Artery Disease; Dibenzothiazepines; Drug Substitution; Female; Humans; Longitudinal Studies; Male; Metabolic Syndrome; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone | 2013 |
Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sex Factors; Young Adult | 2013 |
A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Amino Acids; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Standard of Care; Treatment Outcome; Young Adult | 2013 |
Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Eating; Female; Humans; Insulin Resistance; Male; Mental Disorders; Olanzapine; Piperazines; Postprandial Period; Quinolones; Weight Gain; Young Adult | 2013 |
Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Protocols; Female; Humans; Japan; Longitudinal Studies; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Remission Induction; Research Design; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Adjustment; Treatment Outcome | 2013 |
Predictive value of prospective memory for remission in first-episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; China; Female; Humans; Male; Memory, Episodic; Olanzapine; Piperazines; Prognosis; Quinolones; Remission Induction; Risperidone; Schizophrenia; Treatment Outcome; Young Adult | 2014 |
A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aortic Bodies; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Administration Schedule; Drug Substitution; Female; Humans; Isoxazoles; Male; Middle Aged; Olanzapine; Piperazines; Piperidines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2014 |
Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Substitution; Female; Humans; Isoindoles; Lurasidone Hydrochloride; Male; Middle Aged; Olanzapine; Outpatients; Piperazines; Quality of Life; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2014 |
Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dizziness; Female; Humans; Isoxazoles; Male; Olanzapine; Piperazines; Piperidines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2015 |
The Chinese First-Episode Schizophrenia Trial: background and study design.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; China; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Piperazines; Quinolones; Research Design; Risperidone; Schizophrenia; Treatment Outcome | 2014 |
Schizophrenia gene expression profile reverted to normal levels by antipsychotics.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Humans; Longitudinal Studies; Male; Olanzapine; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Transcriptome; Treatment Outcome | 2014 |
Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Follow-Up Studies; Haloperidol; Humans; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Schizophrenia; Treatment Outcome | 2016 |
Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Specimen Collection; Capillaries; Female; Fingers; Half-Life; Humans; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Risperidone; Veins; Young Adult | 2016 |
Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Comparative Effectiveness Research; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Psychomotor Agitation; Schizophrenia; Treatment Outcome; Young Adult | 2016 |
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Delayed-Action Preparations; Female; Haloperidol; Humans; Hyperprolactinemia; Injections, Intramuscular; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Perphenazine; Proportional Hazards Models; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Failure; Treatment Outcome | 2016 |
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Haloperidol; Humans; Incidence; Male; Olanzapine; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Young Adult | 2017 |
Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial.
Topics: Abdominal Fat; Absorptiometry, Photon; Adolescent; Antipsychotic Agents; Aripiprazole; Child; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Insulin Resistance; Intention to Treat Analysis; Male; Mental Disorders; Olanzapine; Problem Behavior; Risperidone; Treatment Outcome | 2018 |
Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Biosensing Techniques; Cloud Computing; Humans; Medical Informatics Applications; Medication Adherence; Mobile Applications; Multicenter Studies as Topic; Olanzapine; Pragmatic Clinical Trials as Topic; Psychiatry; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Tablets; United Kingdom | 2019 |
An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Olanzapine; Outcome Assessment, Health Care; Risperidone; Schizophrenia; Young Adult | 2019 |
Early Stabilization of Weight Changes Following Treatment With Olanzapine, Risperidone, and Aripiprazole: A 12-Month Naturalistic Study of First Episode Psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; Female; Humans; Male; Olanzapine; Prospective Studies; Psychotic Disorders; Risperidone; Time Factors; Weight Gain; Young Adult | 2019 |
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Follow-Up Studies; Haloperidol; Humans; Male; Olanzapine; Outcome Assessment, Health Care; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Young Adult | 2020 |
Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Male; Metabolic Syndrome; Olanzapine; Piperazines; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Triglycerides | 2020 |
Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Pressure; Dizziness; Electrocardiography; Female; Headache; Heart Rate; Humans; Male; Nausea; Olanzapine; Sleepiness | 2021 |
Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Norway; Olanzapine; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Treatment Outcome; Weight Gain; Young Adult | 2020 |
Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Catechol O-Methyltransferase; Humans; Olanzapine; Pharmacogenetics | 2021 |
Impact of childhood trauma on antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, semi-randomized trial.
Topics: Adverse Childhood Experiences; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Prospective Studies; Risperidone; Schizophrenia | 2022 |
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Haloperidol; Humans; Olanzapine; Quetiapine Fumarate; Risperidone; Schizophrenia; Treatment Outcome | 2023 |
Clinical insight among persons with schizophrenia spectrum disorders treated with amisulpride, aripiprazole or olanzapine: a semi-randomised trial.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Olanzapine; Schizophrenia | 2023 |
Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Olanzapine; Risperidone; Schizophrenia; Treatment Outcome | 2023 |
228 other study(ies) available for aripiprazole and olanzapine
| Article | Year |
|---|---|
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Humans; Protein Binding; Receptors, Histamine H1; Statistics, Nonparametric; Weight Gain | 2003 |
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
Topics: Adenylate Kinase; Animals; Antipsychotic Agents; Enzyme Activation; Hypothalamus; Immunohistochemistry; Mice; Phosphorylation; Receptors, Histamine H1; Weight Gain | 2007 |
Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile.
Topics: Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Binding, Competitive; Biological Availability; Brain; Catalepsy; Cognition; Humans; Indicators and Reagents; Male; Maze Learning; Memory Disorders; Quantitative Structure-Activity Relationship; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Stereotyped Behavior; Sulfonamides | 2007 |
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolactinemia; Indoles; Metabolic Diseases; Phthalimides; Piperazines; Principal Component Analysis; Pyridines; Radioligand Assay; Receptors, Biogenic Amine; Weight Gain | 2007 |
Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Binding Sites; Drug Design; Drug Evaluation, Preclinical; Humans; Ligands; Mice; Models, Molecular; Molecular Structure; Protein Binding; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D3; Structure-Activity Relationship | 2009 |
Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Binding, Competitive; Cell Line; Corpus Striatum; Dopamine; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Discovery; Drug Evaluation, Preclinical; Humans; Ligands; Male; Models, Chemical; Molecular Structure; Motor Activity; Piperazines; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2010 |
Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
Topics: Animals; Antipsychotic Agents; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Ligands; Mice; Models, Molecular; Piperazines; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D3; Structure-Activity Relationship | 2010 |
Novel 7-phenylsulfanyl-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indoles as dual serotonin 5-HT2C and 5-HT6 receptor ligands.
Topics: Cell Line; HeLa Cells; Humans; Indoles; Ligands; Protein Binding; Pyrazines; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Structure-Activity Relationship | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Avoidance Learning; Benzoxazoles; Catalepsy; CHO Cells; Cricetulus; Dementia; Dopamine D2 Receptor Antagonists; HEK293 Cells; Humans; Male; Models, Molecular; Motor Activity; Radioligand Assay; Rats, Wistar; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship; Sulfonamides | 2014 |
Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.
Topics: Amides; Animals; Antipsychotic Agents; Behavior, Animal; Dizocilpine Maleate; Dopamine Antagonists; Drug Evaluation, Preclinical; Female; Kinetics; Ligands; Male; Mice; Prefrontal Cortex; Protein Binding; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D3; Schizophrenia; Serotonin Receptor Agonists; Structure-Activity Relationship | 2014 |
Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold.
Topics: Dose-Response Relationship, Drug; Drug Discovery; Humans; Ligands; Molecular Structure; Quinazolines; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Antagonists; Structure-Activity Relationship | 2015 |
alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brimonidine Tartrate; Chlorpromazine; CHO Cells; Clozapine; Cricetinae; Cyclic AMP; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Humans; Isoxazoles; Norepinephrine; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quetiapine Fumarate; Quinolones; Quinoxalines; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D2; Risperidone; Thiazoles; Transfection; Yohimbine | 2003 |
Similarities and differences among antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2003 |
In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cerebral Cortex; Dopamine; Homovanillic Acid; Hydroxyindoleacetic Acid; Male; Microdialysis; Neostriatum; Olanzapine; Piperazines; Prefrontal Cortex; Quinolones; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin | 2004 |
Aripirazole-olanzapine combination for treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Female; Humans; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2004 |
Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blepharoptosis; Catalepsy; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Head Movements; Male; Methoxydimethyltryptamines; Mice; Mice, Inbred ICR; Olanzapine; Piperazines; Prosencephalon; Quinolones; Rats; Rats, Wistar; Risperidone; Serotonin; Stereotyped Behavior | 2004 |
The risk of harm in mania and the very early time course of improvement: important but neglected variables in treatment research.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Humans; Olanzapine; Piperazines; Quality of Life; Quinolones; Risk Factors; Self-Injurious Behavior; Thiazoles | 2004 |
[Expectations and developments in atypical antipsychotics].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Clozapine; Diabetes Complications; Haloperidol; Humans; Obesity; Olanzapine; Piperazines; Quinolones; Risk Factors; Schizophrenia; Weight Gain | 2004 |
Atypical antipsychotics: matching receptor profile to individual patient's clinical profile.
Topics: Adult; Affect; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Cognition; Dibenzothiazepines; Dose-Response Relationship, Drug; Histamine; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Muscarinic; Receptors, Serotonin; Risperidone; Schizophrenia; Thiazoles | 2004 |
FDA warns antipsychotic drugs may be risky for elderly.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dementia; Dibenzothiazepines; Drug Approval; Drug Labeling; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; United States; United States Food and Drug Administration | 2005 |
Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats.
Topics: Animals; Aripiprazole; Benzodiazepines; Body Weight; Cholesterol, HDL; Fatty Acids, Nonesterified; Female; Olanzapine; Piperazines; Prolactin; Quinolones; Rats; Rats, Sprague-Dawley; Rats, Wistar; Weight Gain | 2005 |
Atypical antipsychotics: special formulations for acute agitation.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Risperidone; Thiazoles | 2005 |
Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Calcium; Cell Line; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Female; Humans; Intracellular Space; Olanzapine; Piperazines; Protein Isoforms; Quinolones; Receptor, Serotonin, 5-HT2C; RNA Editing; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Transfection | 2006 |
Extensive weight loss in a patient with schizophrenia after switching from olanzapine to aripiprazole. A case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy, Combination; Female; Humans; Male; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Loss | 2006 |
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Amenorrhea; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Clozapine; Dibenzothiazepines; Female; Galactorrhea; Gynecomastia; Haloperidol; Humans; Hyperprolactinemia; Male; Olanzapine; Piperazines; Pituitary Neoplasms; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Sex Factors; Thiazoles; United States; United States Food and Drug Administration | 2006 |
A model of anticholinergic activity of atypical antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Binding Sites; Clozapine; Cognition Disorders; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Neuropsychological Tests; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Cholinergic; Risperidone; Schizophrenia; Thiazoles | 2006 |
[Endocrine side effects among psychiatric patients treated with antipsychotics].
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Breast; Dibenzothiazepines; Endocrine System; Female; Galactorrhea; Gynecomastia; Humans; Male; Olanzapine; Piperazines; Prolactin; Quetiapine Fumarate; Quinolones; Schizophrenia; Sulpiride | 2006 |
Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Humans; Male; Metabolic Diseases; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2006 |
Datapoints: The ups and downs of dosing second-generation antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Dose-Response Relationship, Drug; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Thiazoles | 2007 |
The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Haloperidol; Male; Mice; Neural Inhibition; Olanzapine; Phencyclidine; Piperazines; Quinolones; Receptors, Dopamine D2; Reflex, Startle; Schizophrenia | 2007 |
Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole.
Topics: Adult; Amenorrhea; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quinolones | 2007 |
Acute pancreatitis and diabetic ketoacidosis in a schizophrenic patient taking olanzapine.
Topics: Acute Disease; Acute Kidney Injury; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cocaine-Related Disorders; Diabetic Ketoacidosis; Humans; Male; Olanzapine; Pancreatitis; Piperazines; Quinolones; Schizophrenia | 2007 |
Variables affecting prepulse inhibition of the startle reflex and the response to antipsychotics in DBA/2NCrl mice.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Acoustic Stimulation; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; beta-Cyclodextrins; Circadian Rhythm; Excipients; Lighting; Male; Mice; Mice, Inbred DBA; Olanzapine; Piperazines; Quinolones; Reflex, Startle; Species Specificity | 2007 |
Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Electron Transport Complex IV; Energy Metabolism; Haloperidol; Male; Olanzapine; Piperazines; Quinolones; Rats; Rats, Wistar; Succinate Dehydrogenase | 2007 |
Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Female; Haloperidol; In Situ Hybridization; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Muscarinic M1; RNA, Messenger; Time | 2008 |
Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Appetite; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Female; Humans; Male; Metabolic Diseases; Obesity; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2007 |
Practical strategies for assessing and stabilizing bipolar patients in urgent situations.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Emergency Services, Psychiatric; Humans; Impulsive Behavior; Injections, Intramuscular; Olanzapine; Piperazines; Practice Guidelines as Topic; Quinolones; Risperidone; Suicide, Attempted; Thiazoles; Time Factors | 2007 |
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.
Topics: Acute Disease; Adult; Anthropometry; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cholesterol, HDL; Drug Administration Schedule; Female; Humans; Hyperlipidemias; Hypertension; Incidence; Male; Metabolic Syndrome; Olanzapine; Piperazines; Prevalence; Quinolones; Schizophrenia | 2007 |
Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications.
Topics: Administration, Oral; Aged; Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Clozapine; Databases, Factual; Dementia; Dibenzothiazepines; Drug Utilization Review; Health Services for the Aged; Humans; Olanzapine; Pharmaceutical Services; Piperazines; Quetiapine Fumarate; Quinolones; Risk Assessment; Risperidone; Stroke; Thiazoles; Treatment Outcome | 2007 |
Worsened agitation and confusion in schizophrenia subsequent to high-dose aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Humans; Male; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology | 2007 |
Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Eating; Female; Hyperphagia; Motor Activity; Olanzapine; Piperazines; Quinolones; Rats; Thiazoles; Weight Gain | 2008 |
Photo-onycholysis caused by olanzapine and aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Erythema; Female; Humans; Middle Aged; Olanzapine; Onycholysis; Photosensitivity Disorders; Piperazines; Quinolones | 2008 |
Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Fasting; Feeding Behavior; Female; Glucose; Glucose Tolerance Test; Humans; Incidence; Insulin; Male; Middle Aged; Olanzapine; Piperazines; Prevalence; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Time Factors | 2008 |
Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Eating; Female; Haloperidol; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Histamine H1; RNA, Messenger; Time Factors; Ventromedial Hypothalamic Nucleus; Weight Gain | 2008 |
Antipsychotic-induced oxidative stress in rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Corpus Striatum; Haloperidol; Hippocampus; Male; Olanzapine; Oxidative Stress; Piperazines; Prefrontal Cortex; Quinolones; Rats; Rats, Wistar; Superoxides; Thiobarbituric Acid Reactive Substances | 2008 |
Lack of effect of antipsychotics on BNDF and NGF levels in hippocampus of Wistar rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain-Derived Neurotrophic Factor; Clozapine; Drug Administration Schedule; Haloperidol; Hippocampus; Male; Nerve Growth Factor; Olanzapine; Piperazines; Quinolones; Rats; Rats, Wistar; Time; Up-Regulation | 2008 |
The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Benzofurans; Benzoxazoles; Benzylamines; Blood Glucose; Clozapine; Corticosterone; Cyclopentanes; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Haloperidol; Male; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Thiazoles | 2008 |
Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Anxiety; Aripiprazole; Behavior, Animal; Benzodiazepines; Catalepsy; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Indoles; Ketanserin; Male; Mice; Mice, Inbred ICR; Olanzapine; Piperazines; Piperidines; Postural Balance; Psychomotor Performance; Pyridines; Quinolones; Quinpirole; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Serotonin Antagonists; Serotonin Receptor Agonists | 2008 |
Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Haloperidol; Inhibition, Psychological; Male; Mice; Mice, Inbred Strains; Olanzapine; Piperazines; Quinolones; Rats; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Reflex, Startle; Risperidone; Serotonin Receptor Agonists; Species Specificity | 2008 |
Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study.
Topics: Adiponectin; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Dibenzothiazepines; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Insulin-Secreting Cells; Male; Olanzapine; Piperazines; Prospective Studies; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia | 2008 |
A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Cohort Studies; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Netherlands; Olanzapine; Overweight; Piperazines; Quinolones; Schizophrenia | 2008 |
Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
Topics: Algorithms; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials, Phase I as Topic; Cost-Benefit Analysis; Decision Support Techniques; Follow-Up Studies; Health Care Costs; Health Resources; Humans; Olanzapine; Patient Acceptance of Health Care; Piperazines; Quality-Adjusted Life Years; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; United Kingdom | 2008 |
Neuroleptic malignant syndrome with the addition of aripiprazole to olanzapine.
Topics: Adult; Aggression; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Benztropine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Intellectual Disability; Male; Neuroleptic Malignant Syndrome; Neurologic Examination; Olanzapine; Piperazines; Quinolones; Risk Factors | 2008 |
The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Black or African American; Blood Glucose; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Hispanic or Latino; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Obesity; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; White People; Young Adult | 2009 |
Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Brain; Caudate Nucleus; Dopamine; Dopamine Plasma Membrane Transport Proteins; Gene Expression Regulation, Enzymologic; Haloperidol; Limbic System; Nucleus Accumbens; Olanzapine; Piperazines; Putamen; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; RNA, Messenger; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Up-Regulation; Ventral Tegmental Area | 2009 |
Refractory restless legs syndrome likely caused by olanzapine.
Topics: Anticonvulsants; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Middle Aged; Olanzapine; Piperazines; Quinolones; Restless Legs Syndrome; Valproic Acid | 2009 |
Haloperidol changes mRNA expression of a QKI splice variant in human astrocytoma cells.
Topics: Alternative Splicing; Antipsychotic Agents; Aripiprazole; Astrocytoma; Benzodiazepines; Cell Line, Tumor; Clozapine; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Haloperidol; Humans; Olanzapine; Piperazines; Quinolones; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; Risperidone; RNA-Binding Proteins; RNA, Messenger; Time Factors | 2009 |
Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome | 2009 |
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Benzamides; Benzodiazepines; Benzoxazoles; Catalepsy; Clozapine; Dibenzothiazepines; Dioxanes; Dopamine Antagonists; Female; Haloperidol; Macaca fascicularis; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Remoxipride; Risperidone; Serotonin Receptor Agonists; Thiazoles; Tropanes; Video Recording | 2009 |
Maintenance treatment received by patients with bipolar I and II disorders--a naturalistic prospective study.
Topics: Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepine; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lamotrigine; Lithium Carbonate; Long-Term Care; Male; Middle Aged; Olanzapine; Oxcarbazepine; Piperazines; Prospective Studies; Quinolones; Risperidone; Triazines; Valproic Acid | 2010 |
The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Cohort Studies; Diabetes Mellitus; Female; Humans; Male; Mental Disorders; Middle Aged; Olanzapine; Piperazines; Quinolones; Retrospective Studies; Thiazoles; United States | 2009 |
Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Costs and Cost Analysis; Dibenzothiazepines; Drug Therapy, Combination; Female; Health Care Costs; Humans; Male; Middle Aged; Mood Disorders; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Thiazoles; Treatment Outcome; Young Adult | 2009 |
Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Diabetic Ketoacidosis; Dibenzothiazepines; Humans; Mass Screening; Olanzapine; Piperazines; Predictive Value of Tests; Prospective Studies; Quetiapine Fumarate; Quinolones; Severity of Illness Index | 2009 |
Aripiprazole for the management of olanzapine-induced weight gain.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Central Nervous System Agents; Cholesterol; Drug Therapy, Combination; Female; Glucose; Humans; Male; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Treatment Outcome; Triglycerides; Weight Gain | 2009 |
The effects of antipsychotic drugs administration on 5-HT1A receptor expression in the limbic system of the rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Binding Sites; Female; Haloperidol; Limbic System; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Serotonin, 5-HT1; RNA, Messenger | 2009 |
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Composition; Child; Child, Preschool; Cohort Studies; Dibenzothiazepines; Female; Humans; Lipid Metabolism; Lipids; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risk; Risperidone; Weight Gain | 2009 |
Functional SNPs in genes encoding the 5-HT2A receptor modify the affinity and potency of several atypical antipsychotic drugs.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Resistance; HEK293 Cells; Humans; Mutagenesis, Site-Directed; Neuroleptic Malignant Syndrome; Nursing Research; Olanzapine; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Quetiapine Fumarate; Quinolones; Receptor, Serotonin, 5-HT2A; Risperidone; Thiazoles | 2011 |
Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Clozapine; Dibenzothiazepines; Drug Utilization; Evidence-Based Medicine; Female; Humans; Infant; Insurance Claim Review; Male; Medicaid; Mental Disorders; Off-Label Use; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; United States; United States Food and Drug Administration | 2010 |
Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia.
Topics: Acoustic Stimulation; Adult; Aged; Antipsychotic Agents; Aripiprazole; Asian People; Benzodiazepines; Blinking; Female; Humans; Japan; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Reflex, Startle; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Second-generation antipsychotics cause weight gain in youths.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Dibenzothiazepines; Humans; Olanzapine; Overweight; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Weight Gain | 2010 |
Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain-Derived Neurotrophic Factor; Female; Homovanillic Acid; Humans; Longitudinal Studies; Male; Methoxyhydroxyphenylglycol; Middle Aged; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Young Adult | 2010 |
Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Costs; Female; Haloperidol; Humans; Injections, Intramuscular; Length of Stay; Male; Middle Aged; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Retrospective Studies; Schizophrenia; Thiazoles | 2011 |
Aripiprazole add-on treatment in a patient with schizoaffective disorder: neurocognitive outcomes.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Humans; Male; Memory Disorders; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2010 |
Antipsychotic dosing: still a work in progress.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Administration Schedule; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptors, Dopamine D2; Severity of Illness Index | 2010 |
Cochrane for clinicians. Aripiprazole vs. other atypical antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia | 2010 |
Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder.
Topics: Absenteeism; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Cost-Benefit Analysis; Delayed-Action Preparations; Dibenzothiazepines; Drug Therapy, Combination; Fees, Pharmaceutical; Health Care Costs; Hospital Charges; Humans; Lamotrigine; Lithium Compounds; Markov Chains; Models, Economic; Olanzapine; Piperazines; Quality-Adjusted Life Years; Quetiapine Fumarate; Quinolones; Risk; Tablets; Triazines; United States; Valproic Acid | 2010 |
What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Controlled Clinical Trials as Topic; Double-Blind Method; Humans; Obesity; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2010 |
Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington's disease.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Huntington Disease; Male; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Treatment Outcome | 2010 |
Olanzapine abuse was relieved after switching to aripiprazole in a patient with psychotic depression.
Topics: Affective Disorders, Psychotic; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Humans; Middle Aged; Olanzapine; Piperazines; Quinolones; Substance-Related Disorders | 2010 |
Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.
Topics: Adult; Age Factors; Alleles; Amisulpride; Anthropometry; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Composition; Body Mass Index; CLOCK Proteins; Clozapine; Dibenzothiazepines; Drug Therapy, Combination; Female; Genetic Association Studies; Genetic Carrier Screening; Genotype; Humans; Long-Term Care; Male; Middle Aged; Mutation, Missense; Olanzapine; Period Circadian Proteins; Piperazines; Polymorphism, Single Nucleotide; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptor, Melanocortin, Type 3; Receptors, Glucocorticoid; Receptors, Leptin; Risperidone; Schizophrenia; Sex Factors; Sulpiride; Syndecan-3 | 2011 |
Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Choice Behavior; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Glutamic Acid; Haloperidol; Impulsive Behavior; Male; Microdialysis; Neuropsychological Tests; Olanzapine; Piperazines; Prefrontal Cortex; Quinolones; Rats; Reaction Time; Schizophrenia; Serotonin; Time Factors | 2011 |
Neutropenia associated with quetiapine, olanzapine, and aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Female; Humans; Middle Aged; Neutropenia; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Schizophrenia | 2011 |
Aripiprazole protects cortical neurons from glutamate toxicity.
Topics: Animals; Aripiprazole; Benzodiazepines; Cell Nucleus; Cerebral Cortex; Cytoprotection; Dopamine D2 Receptor Antagonists; Glutamic Acid; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Molecular Imaging; Neurons; Neuroprotective Agents; Olanzapine; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolones; Rats; Receptor, Serotonin, 5-HT1A; Risperidone; Serotonin 5-HT1 Receptor Antagonists; Signal Transduction; Tetrazolium Salts; Thiazoles | 2011 |
Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Retrospective Studies; Schizophrenia; Treatment Outcome; United States; Young Adult | 2011 |
A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Topics: Age Factors; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibenzothiazepines; Female; Humans; Inpatients; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risk; Risk Factors; Risperidone; Schizophrenia; Sex Factors; Time Factors; Weight Gain | 2011 |
Management of a patient with schizophrenia and underlying pituitary macroadenoma.
Topics: Adenoma; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bromocriptine; Dopamine Antagonists; Female; Hormone Antagonists; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Pituitary Neoplasms; Quinolones; Risperidone; Schizophrenia; Serotonin Antagonists; Trifluoperazine | 2010 |
Protective effects of atypical antipsychotic drugs against MPP(+)-induced oxidative stress in PC12 cells.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antipsychotic Agents; Aripiprazole; bcl-2-Associated X Protein; Benzodiazepines; Blotting, Western; Cell Survival; Haloperidol; Herbicides; Olanzapine; Oxidative Stress; PC12 Cells; Piperazines; Quinolones; Rats; Reactive Oxygen Species; Superoxide Dismutase; Thiazoles | 2011 |
Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Dibenzothiazepines; Female; Hospitalization; Hospitals, Psychiatric; Humans; Male; Medication Adherence; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Comorbidity; Female; Germany; Humans; Male; Matched-Pair Analysis; Obsessive-Compulsive Disorder; Olanzapine; Piperazines; Prevalence; Quinolones; Schizophrenia; Serotonin Antagonists; Severity of Illness Index; Sulpiride | 2011 |
The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone.
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Asian People; Benzodiazepines; Cohort Studies; Databases, Factual; Female; Hospitals, University; Humans; Male; Medical Records; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Quinolones; Republic of Korea; Retrospective Studies; Risperidone; Schizophrenia; Sex Factors; Young Adult | 2011 |
Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Clozapine; Crime; Delayed-Action Preparations; Dibenzothiazepines; Female; Florida; Humans; Isoxazoles; Male; Medicaid; Middle Aged; Olanzapine; Outpatients; Paliperidone Palmitate; Piperazines; Propensity Score; Pyrimidines; Quetiapine Fumarate; Quinolones; Risk Factors; Risperidone; Schizophrenia; Treatment Outcome; United States; Young Adult | 2011 |
Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Coronary Disease; Costs and Cost Analysis; Female; Humans; Male; Metabolic Diseases; Metabolism; Middle Aged; Olanzapine; Piperazines; Quality-Adjusted Life Years; Quinolones; Risk Assessment; Schizophrenia; Sweden | 2011 |
Changes in the metabolic parameters and QTc interval after switching from olanzapine to aripiprazole in Japanese patients with stable schizophrenia.
Topics: Adolescent; Adult; Aripiprazole; Asian People; Benzodiazepines; Drug Substitution; Female; Heart Rate; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Young Adult | 2011 |
A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; Haloperidol; Humans; Imidazoles; Indoles; Male; Models, Economic; National Health Programs; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Sweden | 2011 |
Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression.
Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Data Interpretation, Statistical; Databases, Factual; Depressive Disorder, Major; Dibenzothiazepines; Drug Costs; Drug Therapy, Combination; Drug Utilization Review; Female; Health Expenditures; Humans; Insurance Claim Review; Male; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Young Adult | 2011 |
Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Female; Gene Expression Regulation; Hyperphagia; Lipid Metabolism; Lipogenesis; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Triglycerides; Weight Gain | 2012 |
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Hallucinations; Haloperidol; Humans; Hungary; Male; Marijuana Abuse; Olanzapine; Paranoid Disorders; Piperazines; Psychomotor Performance; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology | 2011 |
Switching antipsychotic medications: not enough, too often, or just right?
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Drug Substitution; Humans; Hypercholesterolemia; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia | 2011 |
Effects of antipsychotic drugs on BDNF, GSK-3β, and β-catenin expression in rats subjected to immobilization stress.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; beta Catenin; Blotting, Western; Brain-Derived Neurotrophic Factor; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Haloperidol; Hippocampus; Male; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Restraint, Physical; Schizophrenia; Stress, Psychological | 2011 |
Adjunctive antipsychotics for major depression.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Drug Approval; Drug Therapy, Combination; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; United States; United States Food and Drug Administration | 2011 |
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.
Topics: Adolescent; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body Weight; Child; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Spain; Time Factors | 2011 |
[Eosinophilic myocarditis and sudden unexpected death in a younger patient treated with antipsychotics].
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Aripiprazole; Autopsy; Benzodiazepines; Death, Sudden, Cardiac; Drug Therapy, Combination; Eosinophilia; Forensic Pathology; Forensic Toxicology; Humans; Male; Mianserin; Mirtazapine; Myocarditis; Myocardium; Olanzapine; Piperazines; Quinolones; Risk Factors | 2011 |
The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chi-Square Distribution; Clozapine; Dibenzothiazepines; Humans; Missouri; Olanzapine; Piperazines; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Estradiol; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Olanzapine; Pilot Projects; Piperazines; Prolactin; Prospective Studies; Quinolones; Retreatment; Risperidone; Schizophrenia; Sex Hormone-Binding Globulin; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological; Sulpiride; Testosterone | 2012 |
Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Databases, Factual; Dibenzothiazepines; Humans; Isoxazoles; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Publication Bias; Pyrimidines; Quetiapine Fumarate; Quinolones; Risperidone; United States; United States Food and Drug Administration | 2012 |
Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Data Interpretation, Statistical; Dibenzothiazepines; Humans; Olanzapine; Patient Dropouts; Piperazines; Quetiapine Fumarate; Quinolones; Review Literature as Topic; Risperidone; Schizophrenia; Sulpiride | 2012 |
Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients.
Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Auditory Cortex; Benzodiazepines; Dibenzothiazepines; Electroencephalography; Evoked Potentials, Auditory; Female; Humans; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Reaction Time; Receptor, Adenosine A2A; Risperidone; Schizophrenia; Sensory Gating; Up-Regulation | 2012 |
Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Clozapine; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prospective Studies; Quinolones; Risperidone; Schizophrenia; Weight Loss | 2012 |
Synthetic cannabinoid-induced psychosis: two adolescent cases.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cannabinoids; Delusions; Designer Drugs; Humans; Male; Marijuana Abuse; Olanzapine; Piperazines; Psychoses, Substance-Induced; Quinolones | 2012 |
Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
Topics: Adiponectin; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Female; Humans; Lipids; Male; Middle Aged; Obesity; Olanzapine; Piperazines; Prospective Studies; Psychotic Disorders; Quinolones; Weight Gain | 2013 |
Effect of atypical antipsychotics on antioxidant enzyme activities in human erythrocytes (in vitro study).
Topics: Adult; Amisulpride; Antioxidants; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Catalase; Clozapine; Dibenzothiazepines; Enzyme Activation; Erythrocytes; Glutathione Peroxidase; Glutathione Reductase; Humans; Imidazoles; Indoles; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Sulpiride; Superoxide Dismutase; Superoxide Dismutase-1; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Case-Control Studies; Cerebral Cortex; Drug Partial Agonism; Female; Humans; Magnetic Resonance Imaging; Male; Olanzapine; Piperazines; Positron-Emission Tomography; Pyridines; Quinolones; Radiopharmaceuticals; Receptor, Serotonin, 5-HT1A; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2013 |
Consensus statement on the use of intramuscular aripiprazole for the rapid control of agitation in bipolar mania and schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Haloperidol; Humans; Hypnotics and Sedatives; Olanzapine; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia; Tranquilizing Agents | 2013 |
Second-generation antipsychotics cause a rapid switch to fat oxidation that is required for survival in C57BL/6J mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Astemizole; Behavior, Animal; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Drug Interactions; Energy Metabolism; Epoxy Compounds; Fatty Acids; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Motor Activity; Olanzapine; Oxygen Consumption; Piperazines; Quinolones; Receptors, Histamine H1; Respiration; Risperidone; Terfenadine; Time Factors | 2014 |
White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment.
Topics: Adolescent; Adult; Anisotropy; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Brain Mapping; Case-Control Studies; Dibenzothiazepines; Diffusion Tensor Imaging; Female; Frontal Lobe; Gyrus Cinguli; Haloperidol; Humans; Image Processing, Computer-Assisted; Male; Nerve Fibers, Myelinated; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Treatment Outcome; Young Adult | 2013 |
LC-MS/MS of some atypical antipsychotics in human plasma, serum, oral fluid and haemolysed whole blood.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chromatography, Liquid; Clozapine; Dibenzothiazepines; Female; Forensic Toxicology; Hemolysis; Humans; Isoxazoles; Male; Olanzapine; Paliperidone Palmitate; Piperazines; Pyrimidines; Quetiapine Fumarate; Quinolones; Reproducibility of Results; Risperidone; Saliva; Serum; Sulpiride; Tandem Mass Spectrometry | 2013 |
Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Cognition Disorders; Depression; Disease Models, Animal; Drug Administration Schedule; Female; Male; Maze Learning; Memory Disorders; Olanzapine; Piperazines; Pregnancy; Prenatal Exposure Delayed Effects; Quinolones; Rats; Rats, Wistar; Schizophrenia; Stress, Psychological; Time Factors | 2013 |
Stability of some atypical antipsychotics in human plasma, haemolysed whole blood, oral fluid, human serum and calf serum.
Topics: Amisulpride; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cattle; Chromatography, Liquid; Clozapine; Dibenzothiazepines; Drug Stability; Female; Forensic Toxicology; Hemolysis; Humans; Isoxazoles; Male; Olanzapine; Paliperidone Palmitate; Piperazines; Pyrimidines; Quetiapine Fumarate; Quinolones; Reproducibility of Results; Risperidone; Saliva; Serum; Sulpiride; Tandem Mass Spectrometry | 2013 |
Indirect comparison analysis of efficacy and safety between olanzapine and aripiprazole for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Patient Dropouts; Piperazines; Quinolones; Schizophrenia | 2014 |
Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Comorbidity; Female; Humans; Hypochondriasis; Male; Middle Aged; Obsessive-Compulsive Disorder; Olanzapine; Paliperidone Palmitate; Prevalence; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride | 2014 |
Trends in pharmacotherapy in patients referred to a bipolar specialty clinic, 2000-2011.
Topics: Academic Medical Centers; Adult; Ambulatory Care Facilities; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; California; Dibenzothiazepines; Drug Therapy; Female; Humans; Lamotrigine; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Referral and Consultation; Risperidone; Triazines | 2014 |
Despite expert recommendations, second-generation antipsychotics are not often prescribed in the emergency department.
Topics: Administration, Oral; Adult; Alcoholic Intoxication; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Droperidol; Drug Prescriptions; Drug Therapy, Combination; Emergency Service, Hospital; Female; Haloperidol; Hospitals, University; Humans; Male; Middle Aged; Olanzapine; Piperazines; Practice Guidelines as Topic; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles | 2014 |
[Emergency psychopharmacotherapy in Hungary -- preliminary data].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clopenthixol; Droperidol; Drug Prescriptions; Drug Therapy, Combination; Emergency Treatment; Female; Haloperidol; Humans; Hungary; Male; Middle Aged; Olanzapine; Piperazines; Practice Patterns, Physicians'; Promethazine; Psychiatry; Psychomotor Agitation; Psychotic Disorders; Quinolones; Surveys and Questionnaires | 2014 |
Effects of antipsychotic drugs on insight in schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Awareness; Benzodiazepines; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Thiazoles | 2014 |
The influence of aripiprazole, olanzapine and enriched environment on depressant-like behavior, spatial memory dysfunction and hippocampal level of BDNF in prenatally stressed rats.
Topics: Animals; Antidepressive Agents; Aripiprazole; Benzodiazepines; Brain-Derived Neurotrophic Factor; Depression; Environment; Female; Hippocampus; Male; Maze Learning; Memory Disorders; Olanzapine; Piperazines; Pregnancy; Quinolones; Rats; Rats, Wistar; Spatial Memory | 2014 |
Olanzapine-induced triglyceride and aminotransferase elevations without weight gain or hyperglycemia normalized after switching to aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Hypertriglyceridemia; Liver; Male; Olanzapine; Piperazines; Quinolones; Schizophrenia; Transaminases; Treatment Outcome | 2014 |
Neuroleptics and enrichment environment treatment in memory disorders and other central nervous system function observed in prenatally stressed rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Female; Gestational Age; Male; Maze Learning; Memory Disorders; Motor Activity; Olanzapine; Pregnancy; Prenatal Exposure Delayed Effects; Rats, Wistar; Smoking; Social Environment | 2015 |
Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Delirium; Dementia; Female; Haloperidol; Humans; Male; Middle Aged; Olanzapine; Risperidone | 2015 |
Increased orbitofrontal cortex activation associated with "pro-obsessive" antipsychotic treatment in patients with schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Mapping; Clozapine; Executive Function; Female; Humans; Inhibition, Psychological; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Obsessive Behavior; Olanzapine; Piperazines; Prefrontal Cortex; Psychiatric Status Rating Scales; Psychomotor Performance; Quinolones; Schizophrenia; Sulpiride | 2015 |
Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Disease Models, Animal; Epilepsy; Haloperidol; Mental Disorders; Olanzapine; Quetiapine Fumarate; Rats; Risperidone; Seizures | 2015 |
Differential effects of short- and long-term antipsychotic treatment on the expression of neuregulin-1 and ErbB4 receptors in the rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cerebral Cortex; Female; Haloperidol; Hippocampus; Neuregulin-1; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, ErbB-4; Schizophrenia; Signal Transduction; Time Factors; Up-Regulation | 2015 |
Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database.
Topics: Algorithms; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Data Mining; Databases, Factual; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Thiazoles | 2015 |
Temporal and spatial transcriptional fingerprints by antipsychotic or propsychotic drugs in mouse brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Dizocilpine Maleate; Gene Expression Profiling; Gene Expression Regulation; Hallucinogens; Haloperidol; Methamphetamine; Mice; Olanzapine; Phencyclidine; Receptors, Dopamine D2 | 2015 |
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.
Topics: Adolescent; Affective Disorders, Psychotic; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Benzodiazepines; Blood Glucose; Child; Child, Preschool; Cohort Studies; Conduct Disorder; Databases, Factual; Depressive Disorder; Diabetes Mellitus; Female; Glycated Hemoglobin; Guideline Adherence; Humans; Hyperkinesis; Male; Mass Screening; Mental Disorders; Olanzapine; Piperazines; Practice Guidelines as Topic; Practice Patterns, Physicians'; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Risperidone; Thiazoles | 2015 |
Implications of atypical antipsychotic prescribing in the intensive care unit.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Basal Ganglia Diseases; Benzodiazepines; Cohort Studies; Delirium; Disorders of Excessive Somnolence; Female; Humans; Inappropriate Prescribing; Intensive Care Units; Male; Middle Aged; Olanzapine; Patient Discharge; Piperazines; Quetiapine Fumarate; Retrospective Studies; Risperidone; Survivors; Thiazoles | 2015 |
Atypical antipsychotics as augmentation therapy in anorexia nervosa.
Topics: Adult; Anorexia Nervosa; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depression; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Olanzapine; Selective Serotonin Reuptake Inhibitors; Serotonin | 2015 |
Effects of antipsychotic drugs on the expression of synapse-associated proteins in the frontal cortex of rats subjected to immobilization stress.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; beta Catenin; Blotting, Western; Brain-Derived Neurotrophic Factor; Disks Large Homolog 4 Protein; Frontal Lobe; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Haloperidol; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Olanzapine; Rats; Rats, Sprague-Dawley; Stress, Physiological; Synapses; Synaptophysin | 2015 |
Metabolic Impairments Precede Changes in Hunger and Food Intake Following Short-Term Administration of Second-Generation Antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Eating; Ghrelin; Humans; Hunger; Leptin; Metabolic Diseases; Olanzapine; Postprandial Period; Satiety Response; Time Factors | 2015 |
MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol.
Topics: Animals; Aripiprazole; Benzodiazepines; Cannabidiol; Dizocilpine Maleate; Dopamine Antagonists; Male; Memory; Models, Animal; Olanzapine; Rats; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Recognition, Psychology; Risperidone; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Social Behavior | 2015 |
Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Male; Mental Disorders; Multivariate Analysis; New York; Olanzapine; Parkinson Disease, Secondary; Piperazines; Prospective Studies; Quetiapine Fumarate; Regression Analysis; Risperidone; Thiazoles | 2015 |
Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; Finland; Humans; Male; Olanzapine; Paliperidone Palmitate; Risperidone; Schizophrenia | 2016 |
Early antipsychotic treatment in childhood/adolescent period has long-term effects on depressive-like, anxiety-like and locomotor behaviours in adult rats.
Topics: Age Factors; Animals; Antipsychotic Agents; Anxiety; Aripiprazole; Behavior, Animal; Benzodiazepines; Depression; Female; Male; Motor Activity; Olanzapine; Rats; Rats, Sprague-Dawley; Risperidone; Sex Factors; Time Factors | 2016 |
Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Drug Monitoring; Female; Humans; Male; Olanzapine; Quetiapine Fumarate; Risperidone | 2016 |
Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Clozapine; Computer Simulation; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Administration Schedule; Humans; Injections, Intramuscular; Markov Chains; Models, Economic; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; State Medicine; United Kingdom | 2015 |
The influence of aripiprazole and olanzapine on the anxiolytic-like effect observed in prenatally stressed rats (animal model of schizophrenia) exposed to the ethyl alcohol.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Aripiprazole; Behavior, Animal; Benzodiazepines; Disease Models, Animal; Ethanol; Female; Male; Olanzapine; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Schizophrenia; Stress, Psychological | 2016 |
[Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation].
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Depression; Drug Therapy, Combination; Female; Haloperidol; Humans; Hyperprolactinemia; Male; Middle Aged; Olanzapine; Prolactin; Risperidone; Schizophrenia; Schizophrenic Psychology; Young Adult | 2015 |
ADN-1184, a monoaminergic ligand with 5-HT6/7 receptor antagonist action, exhibits activity in animal models of anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Aripiprazole; Behavior, Animal; Benzodiazepines; Conditioning, Psychological; Conflict, Psychological; Disease Models, Animal; Dose-Response Relationship, Drug; Exploratory Behavior; Isoxazoles; Male; Maze Learning; Mice; Motor Activity; Olanzapine; Punishment; Rats, Wistar; Reaction Time; Receptors, Serotonin; Risperidone; Serotonin Antagonists; Sulfonamides | 2016 |
Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Studies as Topic; Flupenthixol; Haloperidol; Humans; Olanzapine; Patient-Centered Care; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Research Design; Schizophrenia | 2016 |
Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth.
Topics: Adolescent; Aripiprazole; Arousal; Benzodiazepines; Child; Cohort Studies; Female; Humans; Male; Olanzapine; Patient Outcome Assessment; Psychomotor Agitation; Quetiapine Fumarate; Risperidone; Schizophrenia, Childhood; Schizophrenic Psychology; Wakefulness | 2016 |
Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Specimen Collection; Capillaries; Female; Fingers; Half-Life; Humans; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Risperidone; Schizophrenia; Veins; Young Adult | 2016 |
Early antipsychotic exposure affects serotonin and dopamine receptor binding density differently in selected brain loci of male and female juvenile rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Autoradiography; Benzodiazepines; Female; Male; Nucleus Accumbens; Olanzapine; Prefrontal Cortex; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia | 2016 |
The influence of aripiprazole and olanzapine on neurotransmitters level in frontal cortex of prenatally stressed rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dopamine; Female; Frontal Lobe; Hydroxyindoleacetic Acid; Neurotransmitter Agents; Norepinephrine; Olanzapine; Pregnancy; Prenatal Exposure Delayed Effects; Rats, Wistar; Serotonin; Stress, Physiological; Stress, Psychological | 2016 |
Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Substitution; Female; Humans; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Patient Satisfaction; Prospective Studies; Risperidone; Schizophrenia; Surveys and Questionnaires; Treatment Outcome | 2017 |
Early Antipsychotic Treatment in Juvenile Rats Elicits Long-Term Alterations to the Dopamine Neurotransmitter System.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Caudate Nucleus; Dopamine; Dopamine Plasma Membrane Transport Proteins; Female; Gene Expression Regulation; Hippocampus; Male; Nucleus Accumbens; Olanzapine; Prefrontal Cortex; Putamen; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Risperidone; Synaptic Transmission; Time Factors; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2016 |
Prescription preferences in antipsychotics and attitude towards the pharmaceutical industry in Belgium.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Belgium; Benzodiazepines; Cross-Sectional Studies; Drug Industry; Drug Prescriptions; Drug Utilization Review; Female; Humans; Male; Middle Aged; Olanzapine; Practice Patterns, Physicians'; Quetiapine Fumarate; Risperidone; Schizophrenia | 2017 |
Development of a UPLC-MS/MS method for routine therapeutic drug monitoring of aripiprazole, amisulpride, olanzapine, paliperidone and ziprasidone with a discussion of their therapeutic reference ranges for Chinese patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; China; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Humans; Limit of Detection; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Piperazines; Reference Values; Tandem Mass Spectrometry; Thiazoles; Young Adult | 2017 |
Olanzapine and aripiprazole differentially affect glucose uptake and energy metabolism in human mononuclear blood cells.
Topics: AMP-Activated Protein Kinase Kinases; Antigens, CD; Antipsychotic Agents; Aripiprazole; Benzodiazepines; DNA Methylation; Dose-Response Relationship, Drug; Excitatory Amino Acid Transporter 2; Flow Cytometry; Fluorodeoxyglucose F18; Gene Expression Regulation; Glucose; Glucose Transporter Type 3; Glutamate Plasma Membrane Transport Proteins; Humans; Ketone Oxidoreductases; Leukocytes, Mononuclear; Olanzapine; Protein Kinases; RNA, Messenger; RNA, Ribosomal, 18S; Statistics, Nonparametric | 2017 |
Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Humans; Insurance Claim Review; Lurasidone Hydrochloride; Male; Medicaid; Medication Adherence; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; United States | 2017 |
Reducing the rehospitalization risk after a manic episode: A population based cohort study of lithium, valproate, olanzapine, quetiapine and aripiprazole in monotherapy and combinations.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Cohort Studies; Drug Therapy, Combination; Female; Hospitalization; Humans; Lithium Compounds; Male; Middle Aged; Olanzapine; Quetiapine Fumarate; Registries; Secondary Prevention; Valproic Acid; Young Adult | 2017 |
Effects of four atypical antipsychotics on autonomic nervous system activity in schizophrenia.
Topics: Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Autonomic Nervous System Diseases; Benzodiazepines; Cross-Sectional Studies; Electrocardiography; Female; Heart Rate; Humans; Japan; Male; Middle Aged; Olanzapine; Psychiatric Status Rating Scales; Quetiapine Fumarate; Retrospective Studies; Risperidone; Schizophrenia | 2018 |
The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.
Topics: Adolescent; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Child; Child, Preschool; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Humans; Male; Neoplasm Proteins; Olanzapine; Pediatrics; Polymorphism, Genetic; Quetiapine Fumarate; Risperidone; Schizophrenia; Young Adult | 2018 |
Chronic atypical antipsychotics, but not haloperidol, increase neurogenesis in the hippocampus of adult mouse.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bromodeoxyuridine; Cell Count; Clozapine; Haloperidol; Hippocampus; Immunohistochemistry; Male; Mice, Inbred C57BL; Neurogenesis; Neurons; Olanzapine; Quetiapine Fumarate | 2017 |
Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost Savings; Delayed-Action Preparations; Female; Health Care Costs; Hospitalization; Humans; Injections; Long-Term Care; Male; Medicaid; Medication Adherence; Middle Aged; Olanzapine; Paliperidone Palmitate; Practice Patterns, Physicians'; Risperidone; Schizophrenia; United States; Young Adult | 2017 |
Olanzapine, blonanserin, and aripiprazole associated with different frontostriatal reward system activation in patients with schizophrenia.
Topics: Adult; Anticipation, Psychological; Antipsychotic Agents; Aripiprazole; Female; Humans; Magnetic Resonance Imaging; Male; Olanzapine; Piperazines; Piperidines; Prefrontal Cortex; Reward; Schizophrenia; Ventral Striatum | 2018 |
Comparative effects of aripiprazole and selected antipsychotic drugs on lipid peroxidation in plasma.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood; Clozapine; Female; Humans; Lipid Peroxidation; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Thiazoles; Thiobarbituric Acid Reactive Substances; Young Adult | 2018 |
The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Comorbidity; Depressive Disorder, Major; Female; Humans; Incidence; Infant; Male; Mental Disorders; Norway; Olanzapine; Prevalence; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia | 2018 |
Determination of plasma concentration reference ranges for oral aripiprazole, olanzapine, and quetiapine.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Female; Humans; Male; Middle Aged; Models, Biological; Olanzapine; Quetiapine Fumarate; Reference Values; Young Adult | 2018 |
The effects of antipsychotics on the density of cannabinoid receptors in selected brain regions of male and female adolescent juvenile rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Autoradiography; Benzodiazepines; Brain; Brain Chemistry; Female; Male; Nucleus Accumbens; Olanzapine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Risperidone; Sex Factors | 2018 |
Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetes, Gestational; Female; Humans; Olanzapine; Piperazines; Pregnancy; Pregnancy Complications; Psychotic Disorders; Quetiapine Fumarate; Risk Factors; Risperidone; Thiazoles; Young Adult | 2018 |
High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Body Mass Index; Cholesterol, HDL; Correlation of Data; Female; Humans; Japan; Male; Middle Aged; Olanzapine; Overweight; Prevalence; Risperidone; Schizophrenia; Surveys and Questionnaires; Waist Circumference | 2018 |
[Using the cumulative odds Logit model to explore the application of the questionnaire derived from PANSS].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Logistic Models; Olanzapine; Risperidone; Schizophrenia; Surveys and Questionnaires | 2016 |
Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; ATP Binding Cassette Transporter, Subfamily B; Autonomic Nervous System; Cross-Sectional Studies; Female; Heart Rate; Humans; Male; Middle Aged; Olanzapine; Polymorphism, Single Nucleotide; Quetiapine Fumarate; Risperidone; Schizophrenia | 2018 |
Chronic antipsychotic treatment differentially modulates protein kinase A- and glycogen synthase kinase 3 beta-dependent signaling pathways, N-methyl-D-aspartate receptor and γ-aminobutyric acid A receptors in nucleus accumbens of juvenile rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Blotting, Western; Cyclic AMP-Dependent Protein Kinases; Glycogen Synthase Kinase 3 beta; Male; Nucleus Accumbens; Olanzapine; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, GABA; Receptors, N-Methyl-D-Aspartate; Risperidone; Signal Transduction | 2018 |
Second generation atypical antipsychotics olanzapine and aripiprazole reduce expression and secretion of inflammatory cytokines in human immune cells.
Topics: Antipsychotic Agents; Aripiprazole; Cytokines; Humans; Inflammation; Leukocytes, Mononuclear; Olanzapine; THP-1 Cells | 2018 |
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cerebral Cortex; Clozapine; Depressive Disorder, Major; Electroencephalography; Female; Humans; Male; Mental Disorders; Middle Aged; Olanzapine; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Young Adult | 2018 |
Chronic Atypical Antipsychotic Use Is Associated With Reduced Need for Postoperative Nausea and Vomiting Rescue in the Postanesthesia Care Unit: A Propensity-Matched Retrospective Observational Study.
Topics: Adult; Aged; Anesthesia Recovery Period; Antiemetics; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Olanzapine; Postoperative Nausea and Vomiting; Propensity Score; Protective Factors; Retrospective Studies; Risk Assessment; Risk Factors; Risperidone; Time Factors | 2020 |
Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.
Topics: Antipsychotic Agents; Aripiprazole; China; Cost-Benefit Analysis; Drug Compounding; Health Resources; Humans; Medication Adherence; Models, Econometric; Olanzapine; Quality-Adjusted Life Years; Recurrence; Schizophrenia | 2019 |
Atypical antipsychotics induce human osteoblasts apoptosis via Wnt/β-catenin signaling.
Topics: Amisulpride; Antipsychotic Agents; Apoptosis; Aripiprazole; beta Catenin; Cell Line; Humans; Olanzapine; Osteoblasts; Resveratrol; Risperidone; Wnt Signaling Pathway | 2019 |
Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Cell Line; Clozapine; Energy Metabolism; Hypothalamus; Inflammation; Insulin; Insulin Resistance; MAP Kinase Signaling System; Neurons; Olanzapine; Phosphorylation; Rats; Schizophrenia; Signal Transduction | 2019 |
Dramatic Weight Loss Following Addition of Aripiprazole to Olanzapine in a Patient With Treatment-resistant Schizophrenia: A Case Report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Substitution; Drug Therapy, Combination; Humans; Male; Olanzapine; Schizophrenia; Weight Loss | 2019 |
c-Fos expression response to olanzapine, amisulpride, aripiprazole, and quetiapine single administration in the rat forebrain: Effect of a mild stress preconditioning.
Topics: Amisulpride; Animals; Antipsychotic Agents; Aripiprazole; Gene Expression; Injections, Intraventricular; Ischemic Preconditioning; Male; Olanzapine; Prosencephalon; Proto-Oncogene Proteins c-fos; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Stress, Psychological | 2019 |
Pathological Concentration of C-reactive Protein is Correlated to Increased Concentrations of Quetiapine, But Not of Risperidone, Olanzapine and Aripiprazole in a Naturalistic Setting.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; C-Reactive Protein; Female; Humans; Inflammation; Leukocyte Count; Male; Middle Aged; Olanzapine; Quetiapine Fumarate; Retrospective Studies; Risperidone; Sex Factors; Young Adult | 2020 |
Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Female; Hospitalization; Humans; Lurasidone Hydrochloride; Male; Middle Aged; Olanzapine; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia | 2019 |
Quantitative efficacy of three antipsychotic drugs for schizophrenia based on a real-world study in China.
Topics: Adult; Antipsychotic Agents; Aripiprazole; China; Female; Humans; Male; Middle Aged; Models, Biological; Olanzapine; Prospective Studies; Risperidone; Schizophrenia; Young Adult | 2019 |
Direct effects of antipsychotic drugs on insulin, energy sensing and inflammatory pathways in hypothalamic mouse neurons.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Cell Line; Clozapine; Energy Metabolism; Heterocyclic Compounds; Hypothalamus; Inflammation; Insulin; Mice; Neurons; Olanzapine; Phosphorylation; Signal Transduction | 2019 |
Spatial relationship between the c-Fos distribution and enkephalinergic, substance P, and tyrosine hydroxylase innervation fields after acute treatment with neuroleptics olanzapine, amisulpride, quetiapine, and aripiprazole in the rat septum.
Topics: Amisulpride; Animals; Antipsychotic Agents; Aripiprazole; Enkephalins; Immunohistochemistry; Male; Neurons; Olanzapine; Proto-Oncogene Proteins c-fos; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Septum of Brain; Substance P; Tissue Distribution; Tyrosine 3-Monooxygenase | 2019 |
Effects of second-generation antipsychotics on human subcutaneous adipose tissue metabolism.
Topics: Abdominal Fat; Adipocytes; Adipogenesis; Adult; Aged; Antipsychotic Agents; Aripiprazole; Cells, Cultured; Dose-Response Relationship, Drug; Female; Humans; Lipid Metabolism; Male; Middle Aged; Olanzapine; Primary Cell Culture; Subcutaneous Fat; Young Adult | 2019 |
Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cohort Studies; Female; Humans; Male; Middle Aged; Olanzapine; Schizophrenia; Treatment Outcome; Young Adult | 2020 |
Treatment of first-episode psychosis in patients with autism-spectrum disorder and intellectual deficiency
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Delusions; Dystonia; Female; Hallucinations; Humans; Hypnotics and Sedatives; Intellectual Disability; Lorazepam; Loxapine; Olanzapine; Paranoid Disorders; Psychotic Disorders; Quetiapine Fumarate; Tourette Syndrome | 2019 |
Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Female; Health Care Costs; Hospitalization; Humans; Lurasidone Hydrochloride; Male; Medicaid; Medicare; Middle Aged; Olanzapine; Paliperidone Palmitate; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Thiophenes; United States | 2020 |
Memory deterioration based on the tobacco smoke exposure and methylazoxymethanol acetate administration vs. aripiprazole, olanzapine and enrichment environment conditions.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Cognition; Disease Models, Animal; Female; Male; Methylazoxymethanol Acetate; Morris Water Maze Test; Neurotoxins; Olanzapine; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Schizophrenia; Spatial Memory; Tobacco Smoke Pollution; Treatment Outcome | 2020 |
The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Olanzapine; Pharmacogenetics; Reflex | 2020 |
Effects of Atypical Antipsychotics on Neuroactive Vitamins in Patients With Schizophrenia.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Case-Control Studies; Female; Humans; Male; Olanzapine; Paliperidone Palmitate; Schizophrenia; Vitamin A; Vitamin D; Vitamin E; Vitamins; Young Adult | 2020 |
c-Fos and FosB/ΔFosB colocalizations in selected forebrain structures after olanzapine, amisulpride, aripiprazole, and quetiapine single administration in rats preconditioned by two different mild stressors sequences.
Topics: Amisulpride; Animals; Antipsychotic Agents; Aripiprazole; Corpus Striatum; Male; Olanzapine; Proto-Oncogene Proteins c-fos; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Septal Nuclei; Stress, Psychological | 2020 |
Effect of amisulpride, olanzapine, quetiapine, and aripiprazole single administration on c-Fos expression in vasopressinergic and oxytocinergic neurons of the rat hypothalamic supraoptic nucleus.
Topics: Amisulpride; Animals; Antipsychotic Agents; Aripiprazole; Male; Neurons; Olanzapine; Oxytocin; Proto-Oncogene Proteins c-fos; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Supraoptic Nucleus; Vasopressins | 2020 |
Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China.
Topics: Administration, Oral; Antipsychotic Agents; Aripiprazole; China; Computer Simulation; Cost-Benefit Analysis; Drug Delivery Systems; Humans; Medication Adherence; Olanzapine; Quality-Adjusted Life Years; Recurrence; Schizophrenia; Tablets | 2020 |
Identification and Quantification of Antipsychotics in Blood Samples by LC-MS-MS: Case Reports and Data from Three Years of Routine Analysis.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chromatography, Liquid; Clozapine; Dibenzothiazepines; Female; Forensic Toxicology; Humans; Male; Olanzapine; Paliperidone Palmitate; Piperazines; Quetiapine Fumarate; Retrospective Studies; Risperidone; Schizophrenia; Substance Abuse Detection; Suicide; Sulpiride; Tandem Mass Spectrometry; Thiazoles | 2020 |
What is the "best intro"-explanatory versus pragmatic antipsychotic drug trials.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Olanzapine; Schizophrenia | 2020 |
Pragmatic antipsychotics trial-caution in interpretation.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Olanzapine; Schizophrenia | 2021 |
Pragmatic antipsychotics trial-caution in interpretation - Authors' reply.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Humans; Olanzapine; Schizophrenia | 2021 |
Antipsychotic Treatment Duration in Children and Adolescents: A Register-Based Nationwide Study.
Topics: Adolescent; Aged; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Duration of Therapy; Female; Finland; Humans; Infant; Infant, Newborn; Male; Off-Label Use; Olanzapine; Quetiapine Fumarate; Risperidone; Schizophrenia | 2021 |
A Comparative Study of Aripiprazole, Olanzapine, and L-Methylfolate Augmentation in Treatment Resistant Obsessive-Compulsive Disorder.
Topics: Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Humans; Obsessive-Compulsive Disorder; Olanzapine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Tetrahydrofolates; Treatment Outcome | 2021 |
The effect of amisulpride, olanzapine, quetiapine, and aripiprazole single administration on c-Fos expression in vasopressinergic and oxytocinergic neurons of the rat hypothalamic paraventricular nucleus.
Topics: Amisulpride; Animals; Antipsychotic Agents; Aripiprazole; Fluorescent Dyes; Gene Expression Regulation; Genes, fos; Male; Neurons; Olanzapine; Oxytocin; Paraventricular Hypothalamic Nucleus; Proto-Oncogene Proteins c-fos; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Staining and Labeling; Vasopressins | 2021 |
Catatonic Symptoms Successfully Treated with Olanzapine in an Adolescent with Schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Catatonia; Humans; Male; Olanzapine; Schizophrenia | 2021 |
A comparative study of olanzapine, aripiprazole and risperidone in the treatment of psychiatric and behavioral symptoms of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Olanzapine; Retrospective Studies; Risperidone; Time Factors; Treatment Outcome | 2021 |
The second-generation antipsychotic drug aripiprazole modulates the serotonergic system in pancreatic islets and induces beta cell dysfunction in female mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Diabetes Mellitus, Type 2; Female; Humans; Islets of Langerhans; Mice; Olanzapine | 2022 |
Can pediatric bipolar disorder be successfully treated when comorbid with conduct disorder? A secondary analysis of clinical trials of risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Child; Clinical Trials as Topic; Conduct Disorder; Humans; Mania; Olanzapine; Piperazines; Prospective Studies; Quetiapine Fumarate; Risperidone; Thiazoles | 2022 |
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System.
Topics: Antipsychotic Agents; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Dopamine Agonists; Humans; Hyperphagia; Lurasidone Hydrochloride; Olanzapine; Pharmacovigilance; Quinolones; Receptors, Serotonin; Thiophenes; United States; United States Food and Drug Administration | 2022 |
Metformin ameliorates olanzapine-induced disturbances in POMC neuron number, axonal projection, and hypothalamic leptin resistance.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Female; Hypothalamus; Leptin; Metformin; Mice; Neurons; Obesity; Olanzapine; Pro-Opiomelanocortin | 2022 |
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Clozapine; Drug-Related Side Effects and Adverse Reactions; Haloperidol; Humans; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Retrospective Studies; Risperidone; Schizophrenia | 2022 |
Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Topics: Adenosine Monophosphate; Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Clopenthixol; Clozapine; Flupenthixol; Fluphenazine; Haloperidol; Humans; Olanzapine; Paliperidone Palmitate; Pharmaceutical Preparations; Pimozide; Quetiapine Fumarate; Risperidone; Sulpiride; Trifluoperazine | 2022 |
Effects of Psychotropic Drugs on Ribosomal Genes and Protein Synthesis.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Humans; Lithium; Olanzapine; Psychotropic Drugs; Quetiapine Fumarate; Ribosomes | 2022 |
Antipsychotic Drug Aripiprazole Protects Liver Cells from Oxidative Stress.
Topics: Antioxidants; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chemical and Drug Induced Liver Injury; Hepatocytes; Humans; Hydrogen Peroxide; Olanzapine; Oxidative Stress | 2022 |
The long-lasting effects of early antipsychotic exposure during juvenile period on adult behaviours - A study in a poly I:C rat model.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Olanzapine; Poly I-C; Pregnancy; Rats; Risperidone | 2022 |
Integrating machine learning with electronic health record data to facilitate detection of prolactin level and pharmacovigilance signals in olanzapine-treated patients.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Electronic Health Records; Humans; Machine Learning; Male; Olanzapine; Pharmacovigilance; Prolactin; Risperidone | 2022 |
Effects of the second-generation antipsychotic drugs aripiprazole and olanzapine on human adipocyte differentiation.
Topics: Adipocytes; Antipsychotic Agents; Aripiprazole; Diabetes Mellitus, Type 2; Humans; Olanzapine; Piperazines | 2023 |
The impact of adjunctive aripiprazole on QT interval: A 12-week open label study in patients on olanzapine, clozapine or risperidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Humans; Olanzapine; Piperazines; Prospective Studies; Risperidone | 2023 |
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quinolones; Recurrence; Schizophrenia | 2023 |
Antipsychotic-Related Prolactin Levels and Sexual Dysfunction in Mentally Ill Youth: A 3-Month Cohort Study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cohort Studies; Erectile Dysfunction; Female; Galactorrhea; Humans; Hyperprolactinemia; Male; Mentally Ill Persons; Olanzapine; Pregnancy; Prolactin; Prospective Studies; Quetiapine Fumarate; Risperidone | 2023 |
Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Humans; Olanzapine; Risperidone; Schizophrenia; Weight Gain | 2023 |
Therapeutic outcomes wide association scan of different antipsychotics in patients with schizophrenia: Randomized clinical trials and multi-ancestry validation.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Lipids; Olanzapine; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Treatment Outcome | 2023 |
Prediction of treatment response to antipsychotic drugs for precision medicine approach to schizophrenia: randomized trials and multiomics analysis.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Multiomics; Olanzapine; Phospholipases; Precision Medicine; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2023 |
Comparison between olanzapine and aripiprazole treatment for 104 weeks after hospital discharge in schizophrenia spectrum disorders: a multicenter retrospective cohort study in a real-world setting.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Hospitals; Humans; Olanzapine; Patient Discharge; Piperazines; Quinolones; Retrospective Studies; Schizophrenia | 2023 |
Aripiprazole-Associated Rhabdomyolysis in a 17-Year-Old Male.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Humans; Male; Olanzapine; Rhabdomyolysis; Risperidone | 2023 |
Predictors of hospitalisation and recovery following full antipsychotic discontinuation in first episode psychosis. A naturalistic retrospective cohort study.
Topics: Antipsychotic Agents; Aripiprazole; Hospitalization; Humans; Olanzapine; Psychotic Disorders; Retrospective Studies | 2023 |